https://trial.medpath.com/news/fda-rejects-atara-s-cell-therapy-for-rare-transplant-complication 2025-01-17T07:31:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-rejects-atara-s-cell-therapy-for-rare-transplant-complication 2025-01-17T07:31:10+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-misleading-marketing-practices-in-online-sales-of-compounded-glp-1-medications 2025-01-17T07:10:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-misleading-marketing-practices-in-online-sales-of-compounded-glp-1-medications 2025-01-17T07:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-novel-combination-therapies-for-colorectal-cancer-and-mantle-cell-lymphoma 2025-01-17T06:29:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-novel-combination-therapies-for-colorectal-cancer-and-mantle-cell-lymphoma 2025-01-17T06:29:28+00:00 hourly 0.9 https://trial.medpath.com/news/hhs-expands-medicare-price-negotiations-with-15-new-drugs-including-ozempic-and-trelegy-ellipta 2025-01-17T06:07:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hhs-expands-medicare-price-negotiations-with-15-new-drugs-including-ozempic-and-trelegy-ellipta 2025-01-17T06:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/active-surveillance-in-intermediate-risk-prostate-cancer-doubles-over-past-decade-yale-study-shows 2025-01-17T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/active-surveillance-in-intermediate-risk-prostate-cancer-doubles-over-past-decade-yale-study-shows 2025-01-17T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/arcturus-therapeutics-advances-in-cystic-fibrosis-and-otcd-treatments-with-promising-clinical-trials 2025-01-17T05:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arcturus-therapeutics-advances-in-cystic-fibrosis-and-otcd-treatments-with-promising-clinical-trials 2025-01-17T05:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/non-toxic-bacteria-cancer-treatment-advances-toward-clinical-trials 2025-01-17T04:58:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/non-toxic-bacteria-cancer-treatment-advances-toward-clinical-trials 2025-01-17T04:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/lymex-diagnostics-prize-announces-phase-3-winners-paving-the-way-for-advanced-lyme-disease-diagnostics 2025-01-17T04:31:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lymex-diagnostics-prize-announces-phase-3-winners-paving-the-way-for-advanced-lyme-disease-diagnostics 2025-01-17T04:31:41+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-drug-omjjara-approved-in-australia-for-rare-bone-marrow-cancer-treatment 2025-01-17T04:31:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-drug-omjjara-approved-in-australia-for-rare-bone-marrow-cancer-treatment 2025-01-17T04:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/medicare-to-negotiate-single-price-for-novo-s-semaglutide-products-including-ozempic-and-wegovy 2025-01-17T04:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicare-to-negotiate-single-price-for-novo-s-semaglutide-products-including-ozempic-and-wegovy 2025-01-17T04:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/shionogi-advances-development-of-long-acting-covid-19-antiviral-with-barda-support 2025-01-17T04:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shionogi-advances-development-of-long-acting-covid-19-antiviral-with-barda-support 2025-01-17T04:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/texas-judge-allows-states-to-challenge-fda-s-mifepristone-access-guidelines 2025-01-17T03:25:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/texas-judge-allows-states-to-challenge-fda-s-mifepristone-access-guidelines 2025-01-17T03:25:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-leads-global-drug-approvals-in-2024-with-50-novel-medicines-outpacing-ema-s-46 2025-01-17T03:02:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-leads-global-drug-approvals-in-2024-with-50-novel-medicines-outpacing-ema-s-46 2025-01-17T03:02:53+00:00 hourly 0.9 https://trial.medpath.com/news/sofia-catheter-shows-97-success-rate-in-acute-stroke-treatment-study 2025-01-17T02:54:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sofia-catheter-shows-97-success-rate-in-acute-stroke-treatment-study 2025-01-17T02:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-lumakras-combined-with-vectibix-for-kras-g12c-metastatic-colorectal-cancer 2025-01-17T02:31:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-lumakras-combined-with-vectibix-for-kras-g12c-metastatic-colorectal-cancer 2025-01-17T02:31:17+00:00 hourly 0.9 https://trial.medpath.com/news/combining-aerobic-exercise-with-phono-motor-treatment-shows-promise-for-aphasia-recovery 2025-01-17T01:32:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/combining-aerobic-exercise-with-phono-motor-treatment-shows-promise-for-aphasia-recovery 2025-01-17T01:32:16+00:00 hourly 0.9 https://trial.medpath.com/news/lyndra-therapeutics-partners-with-thermo-fisher-for-long-acting-oral-therapies-manufacturing 2025-01-17T01:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lyndra-therapeutics-partners-with-thermo-fisher-for-long-acting-oral-therapies-manufacturing 2025-01-17T01:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/rising-interest-in-left-bundle-branch-area-pacing-lbbap-for-cardiac-treatment 2025-01-17T01:31:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rising-interest-in-left-bundle-branch-area-pacing-lbbap-for-cardiac-treatment 2025-01-17T01:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-acalabrutinib-combination-therapy-for-untreated-mantle-cell-lymphoma 2025-01-17T01:31:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-acalabrutinib-combination-therapy-for-untreated-mantle-cell-lymphoma 2025-01-17T01:31:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-sotorasib-plus-panitumumab-for-kras-g12c-mutated-colorectal-cancer 2025-01-17T01:31:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-sotorasib-plus-panitumumab-for-kras-g12c-mutated-colorectal-cancer 2025-01-17T01:31:11+00:00 hourly 0.9 https://trial.medpath.com/news/five-advanced-therapeutics-poised-for-fda-decisions-in-2025 2025-01-17T01:30:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/five-advanced-therapeutics-poised-for-fda-decisions-in-2025 2025-01-17T01:30:57+00:00 hourly 0.9 https://trial.medpath.com/news/abeona-therapeutics-advances-pz-cel-gene-therapy-for-rdeb-with-fda-bla-resubmission 2025-01-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abeona-therapeutics-advances-pz-cel-gene-therapy-for-rdeb-with-fda-bla-resubmission 2025-01-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/orserdu-shows-promise-in-real-world-breast-cancer-treatment-highlighting-need-for-access 2025-01-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orserdu-shows-promise-in-real-world-breast-cancer-treatment-highlighting-need-for-access 2025-01-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-advances-show-promise-for-pediatric-osteosarcoma-treatment 2025-01-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunotherapy-advances-show-promise-for-pediatric-osteosarcoma-treatment 2025-01-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-prostate-cancer-trials-reveal-mixed-results-chaarted2-shows-promise-while-cyclone-2-disappoints 2025-01-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-prostate-cancer-trials-reveal-mixed-results-chaarted2-shows-promise-while-cyclone-2-disappoints 2025-01-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-updated-covid-19-vaccines-targeting-kp-2-variant-for-2024-25-season 2025-01-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-updated-covid-19-vaccines-targeting-kp-2-variant-for-2024-25-season 2025-01-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/promising-phase-iii-results-for-once-a-month-hiv-treatment 2025-01-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/promising-phase-iii-results-for-once-a-month-hiv-treatment 2025-01-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-extends-review-period-for-biogen-s-sod1-als-therapy-tofersen 2025-01-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-extends-review-period-for-biogen-s-sod1-als-therapy-tofersen 2025-01-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/actinogen-expands-digital-cognitive-assessment-suite-in-phase-2b-3-alzheimer-s-trial 2025-01-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actinogen-expands-digital-cognitive-assessment-suite-in-phase-2b-3-alzheimer-s-trial 2025-01-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/myriadtm-matrix-shows-95-success-rate-in-high-risk-limb-salvage-surgery-new-study-reports 2025-01-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/myriadtm-matrix-shows-95-success-rate-in-high-risk-limb-salvage-surgery-new-study-reports 2025-01-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-industry-faces-complex-challenges-in-2025-adaptive-designs-political-shifts-and-diversity-requirements 2025-01-16T23:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-industry-faces-complex-challenges-in-2025-adaptive-designs-political-shifts-and-diversity-requirements 2025-01-16T23:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-data-from-af-symposium-2025-highlights-advances-in-atrial-fibrillation-treatment 2025-01-16T22:39:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-data-from-af-symposium-2025-highlights-advances-in-atrial-fibrillation-treatment 2025-01-16T22:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/multifocal-contact-lenses-show-long-term-benefits-in-slowing-myopia-progression-in-children 2025-01-16T22:33:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multifocal-contact-lenses-show-long-term-benefits-in-slowing-myopia-progression-in-children 2025-01-16T22:33:20+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-reveals-no-survival-benefit-from-triplet-chemotherapy-in-advanced-biliary-tract-cancers 2025-01-16T22:33:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-reveals-no-survival-benefit-from-triplet-chemotherapy-in-advanced-biliary-tract-cancers 2025-01-16T22:33:01+00:00 hourly 0.9 https://trial.medpath.com/news/drug-toxicity-leads-to-early-discontinuation-of-niraparib-in-ovarian-cancer-treatment 2025-01-16T22:32:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/drug-toxicity-leads-to-early-discontinuation-of-niraparib-in-ovarian-cancer-treatment 2025-01-16T22:32:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-immobilized-lipase-cartridge-clearance-to-include-children-as-young-as-1-year 2025-01-16T22:32:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-immobilized-lipase-cartridge-clearance-to-include-children-as-young-as-1-year 2025-01-16T22:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/advancements-in-brain-cancer-treatment-a-look-into-novel-drug-classes-and-clinical-trials 2025-01-16T22:32:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancements-in-brain-cancer-treatment-a-look-into-novel-drug-classes-and-clinical-trials 2025-01-16T22:32:11+00:00 hourly 0.9 https://trial.medpath.com/news/trinidad-makes-history-with-first-oncology-clinical-trial-amidst-pandemic-challenges 2025-01-16T22:31:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trinidad-makes-history-with-first-oncology-clinical-trial-amidst-pandemic-challenges 2025-01-16T22:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/kadcyla-shows-significant-survival-benefits-in-her2-positive-early-breast-cancer-patients-katherine-trial-reveals 2025-01-16T22:31:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kadcyla-shows-significant-survival-benefits-in-her2-positive-early-breast-cancer-patients-katherine-trial-reveals 2025-01-16T22:31:31+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trials-offer-new-hope-in-the-fight-against-multidrug-resistant-tuberculosis 2025-01-16T22:31:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trials-offer-new-hope-in-the-fight-against-multidrug-resistant-tuberculosis 2025-01-16T22:31:16+00:00 hourly 0.9 https://trial.medpath.com/news/ad04-13-study-confirms-consistent-bioavailability-and-safety-for-alcohol-use-disorder-treatment 2025-01-16T22:31:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ad04-13-study-confirms-consistent-bioavailability-and-safety-for-alcohol-use-disorder-treatment 2025-01-16T22:31:03+00:00 hourly 0.9 https://trial.medpath.com/news/evolving-treatment-landscape-in-advanced-clear-cell-renal-cell-carcinoma-highlighted-in-recent-clinical-trials 2025-01-16T22:30:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evolving-treatment-landscape-in-advanced-clear-cell-renal-cell-carcinoma-highlighted-in-recent-clinical-trials 2025-01-16T22:30:53+00:00 hourly 0.9 https://trial.medpath.com/news/cuba-advances-in-adult-pneumococcal-protection-with-new-11-valent-vaccine-candidate 2025-01-16T19:32:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cuba-advances-in-adult-pneumococcal-protection-with-new-11-valent-vaccine-candidate 2025-01-16T19:32:26+00:00 hourly 0.9 https://trial.medpath.com/news/trastuzumab-pertuzumab-shows-promise-for-her2-positive-metastatic-colorectal-cancer 2025-01-16T19:32:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trastuzumab-pertuzumab-shows-promise-for-her2-positive-metastatic-colorectal-cancer 2025-01-16T19:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/bimekizumab-shows-promising-results-in-reducing-pain-and-fatigue-in-psoriatic-arthritis-patients 2025-01-16T19:31:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bimekizumab-shows-promising-results-in-reducing-pain-and-fatigue-in-psoriatic-arthritis-patients 2025-01-16T19:31:49+00:00 hourly 0.9 https://trial.medpath.com/news/aspen-neuroscience-s-anpd001-shows-promise-in-early-parkinson-s-disease-trial 2025-01-16T19:31:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aspen-neuroscience-s-anpd001-shows-promise-in-early-parkinson-s-disease-trial 2025-01-16T19:31:29+00:00 hourly 0.9 https://trial.medpath.com/news/exercise-therapy-emerges-as-a-promising-anticancer-strategy-in-clinical-trials 2025-01-16T19:31:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exercise-therapy-emerges-as-a-promising-anticancer-strategy-in-clinical-trials 2025-01-16T19:31:09+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-s-linq-icms-outperform-apple-watch-in-afib-detection-study-reveals 2025-01-16T18:53:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-s-linq-icms-outperform-apple-watch-in-afib-detection-study-reveals 2025-01-16T18:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/titan-mining-advances-natural-flake-graphite-production-with-phase-iii-metallurgy-results 2025-01-16T16:33:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/titan-mining-advances-natural-flake-graphite-production-with-phase-iii-metallurgy-results 2025-01-16T16:33:29+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-s-iclepertin-fails-to-meet-primary-endpoints-in-phase-iii-schizophrenia-trials 2025-01-16T16:33:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boehringer-ingelheim-s-iclepertin-fails-to-meet-primary-endpoints-in-phase-iii-schizophrenia-trials 2025-01-16T16:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-bile-duct-cancer-treatment-safir-abc10-trial-offers-new-hope 2025-01-16T16:32:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-in-bile-duct-cancer-treatment-safir-abc10-trial-offers-new-hope 2025-01-16T16:32:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-preludedx-s-dcisionrt-test-for-dcis 2025-01-16T16:32:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-device-designation-to-preludedx-s-dcisionrt-test-for-dcis 2025-01-16T16:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-pharmaceuticals-awaits-fda-decision-on-suzetrigine-for-acute-pain-treatment 2025-01-16T16:32:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertex-pharmaceuticals-awaits-fda-decision-on-suzetrigine-for-acute-pain-treatment 2025-01-16T16:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/atara-biotherapeutics-receives-fda-complete-response-letter-for-ebvallotm-tabelecleucel 2025-01-16T16:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atara-biotherapeutics-receives-fda-complete-response-letter-for-ebvallotm-tabelecleucel 2025-01-16T16:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/inflarx-s-gohibic-receives-eu-approval-for-covid-19-related-ards-treatment 2025-01-16T16:31:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inflarx-s-gohibic-receives-eu-approval-for-covid-19-related-ards-treatment 2025-01-16T16:31:43+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-brain-cancer-treatment-phase-0-1-trial-for-brain-penetrant-egfr-inhibitor 2025-01-16T16:31:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-in-brain-cancer-treatment-phase-0-1-trial-for-brain-penetrant-egfr-inhibitor 2025-01-16T16:31:27+00:00 hourly 0.9 https://trial.medpath.com/news/emerging-treatments-for-non-ccrcc-insights-from-recent-clinical-trials 2025-01-16T16:31:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emerging-treatments-for-non-ccrcc-insights-from-recent-clinical-trials 2025-01-16T16:31:12+00:00 hourly 0.9 https://trial.medpath.com/news/innovative-neck-stent-in-clinical-trials-shows-promise-in-stroke-prevention 2025-01-16T16:30:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovative-neck-stent-in-clinical-trials-shows-promise-in-stroke-prevention 2025-01-16T16:30:58+00:00 hourly 0.9 https://trial.medpath.com/news/radiomics-in-rectal-cancer-a-powerful-tool-for-diagnosis-treatment-response-evaluation-and-prognosis-prediction 2025-01-16T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radiomics-in-rectal-cancer-a-powerful-tool-for-diagnosis-treatment-response-evaluation-and-prognosis-prediction 2025-01-16T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/harvard-dermatologist-champions-physician-advocacy-and-women-s-leadership-in-healthcare-policy 2025-01-16T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harvard-dermatologist-champions-physician-advocacy-and-women-s-leadership-in-healthcare-policy 2025-01-16T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/kent-hospital-s-enhanced-mpn-care-program-shows-improved-patient-outcomes-through-personalized-support 2025-01-16T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kent-hospital-s-enhanced-mpn-care-program-shows-improved-patient-outcomes-through-personalized-support 2025-01-16T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/hudson-therapeutics-advances-to-phase-2b-part-2-for-nugel-in-atopic-dermatitis-treatment 2025-01-16T14:47:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hudson-therapeutics-advances-to-phase-2b-part-2-for-nugel-in-atopic-dermatitis-treatment 2025-01-16T14:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/uk-researchers-explore-medical-marijuana-for-late-stage-dementia-symptoms 2025-01-16T14:46:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-researchers-explore-medical-marijuana-for-late-stage-dementia-symptoms 2025-01-16T14:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/higher-cumulative-isotretinoin-dosage-linked-to-lower-acne-recurrence-rates-large-study-finds 2025-01-16T14:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/higher-cumulative-isotretinoin-dosage-linked-to-lower-acne-recurrence-rates-large-study-finds 2025-01-16T14:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/ocugen-inc-initiates-phase-1-clinical-trial-for-ocu200-in-diabetic-macular-edema-treatment 2025-01-16T13:31:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ocugen-inc-initiates-phase-1-clinical-trial-for-ocu200-in-diabetic-macular-edema-treatment 2025-01-16T13:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/lerociclib-plus-fulvestrant-shows-promising-results-in-hr-her2-advanced-breast-cancer 2025-01-16T13:31:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lerociclib-plus-fulvestrant-shows-promising-results-in-hr-her2-advanced-breast-cancer 2025-01-16T13:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/neoadjuvant-t-vec-therapy-shows-promise-in-treating-difficult-to-resect-basal-cell-carcinoma 2025-01-16T13:31:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neoadjuvant-t-vec-therapy-shows-promise-in-treating-difficult-to-resect-basal-cell-carcinoma 2025-01-16T13:31:22+00:00 hourly 0.9 https://trial.medpath.com/news/breast-cancer-drug-in-clinical-trials-shows-promise-for-treating-blood-cancers 2025-01-16T13:30:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breast-cancer-drug-in-clinical-trials-shows-promise-for-treating-blood-cancers 2025-01-16T13:30:58+00:00 hourly 0.9 https://trial.medpath.com/news/urogen-pharma-advances-in-urothelial-cancer-treatment-with-promising-clinical-trial-results 2025-01-16T11:30:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/urogen-pharma-advances-in-urothelial-cancer-treatment-with-promising-clinical-trial-results 2025-01-16T11:30:55+00:00 hourly 0.9 https://trial.medpath.com/news/adjuvant-ado-trastuzumab-emtansine-shows-long-term-survival-benefits-in-early-her2-positive-breast-cancer 2025-01-16T11:01:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adjuvant-ado-trastuzumab-emtansine-shows-long-term-survival-benefits-in-early-her2-positive-breast-cancer 2025-01-16T11:01:14+00:00 hourly 0.9 https://trial.medpath.com/news/dual-diagnosis-of-aortic-stenosis-and-cardiac-amyloidosis-linked-to-higher-mortality-risk-study-shows 2025-01-16T09:34:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-diagnosis-of-aortic-stenosis-and-cardiac-amyloidosis-linked-to-higher-mortality-risk-study-shows 2025-01-16T09:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-significant-racial-disparities-in-bariatric-surgery-progression-rates 2025-01-16T09:21:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-significant-racial-disparities-in-bariatric-surgery-progression-rates 2025-01-16T09:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/alligator-bioscience-advances-mitazalimab-to-phase-3-with-positive-regulatory-feedback 2025-01-16T09:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alligator-bioscience-advances-mitazalimab-to-phase-3-with-positive-regulatory-feedback 2025-01-16T09:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/hsp60-expression-levels-emerge-as-critical-prognostic-marker-in-ovarian-cancer-study 2025-01-16T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hsp60-expression-levels-emerge-as-critical-prognostic-marker-in-ovarian-cancer-study 2025-01-16T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/historic-healthcare-strike-in-oregon-thousands-of-providence-health-workers-demand-better-working-conditions 2025-01-16T08:56:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/historic-healthcare-strike-in-oregon-thousands-of-providence-health-workers-demand-better-working-conditions 2025-01-16T08:56:04+00:00 hourly 0.9 https://trial.medpath.com/news/european-readi-consortium-launches-eur66-8m-initiative-to-boost-clinical-trial-diversity 2025-01-16T08:41:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-readi-consortium-launches-eur66-8m-initiative-to-boost-clinical-trial-diversity 2025-01-16T08:41:07+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-atara-biotherapeutics-blood-cancer-treatment-shares-plunge 2025-01-16T08:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-rejects-atara-biotherapeutics-blood-cancer-treatment-shares-plunge 2025-01-16T08:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-shows-growing-support-for-advanced-and-otc-access-to-medication-abortion-post-dobbs 2025-01-16T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-shows-growing-support-for-advanced-and-otc-access-to-medication-abortion-post-dobbs 2025-01-16T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-historic-marketing-authorization-for-zyn-nicotine-pouches-despite-youth-usage-concerns 2025-01-16T07:36:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-historic-marketing-authorization-for-zyn-nicotine-pouches-despite-youth-usage-concerns 2025-01-16T07:36:50+00:00 hourly 0.9 https://trial.medpath.com/news/keros-therapeutics-halts-pah-trial-following-safety-concerns-with-cibotercept 2025-01-16T06:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/keros-therapeutics-halts-pah-trial-following-safety-concerns-with-cibotercept 2025-01-16T06:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-studies-validate-jak-inhibitors-effectiveness-in-rheumatoid-arthritis-treatment 2025-01-16T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-studies-validate-jak-inhibitors-effectiveness-in-rheumatoid-arthritis-treatment 2025-01-16T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/medipharm-labs-extends-deadline-for-5-5m-napanee-facility-sale-to-kensana-health 2025-01-16T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medipharm-labs-extends-deadline-for-5-5m-napanee-facility-sale-to-kensana-health 2025-01-16T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/iteos-therapeutics-reports-encouraging-phase-2-results-for-belrestotug-dostarlimab-combination-in-nsclc 2025-01-16T05:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iteos-therapeutics-reports-encouraging-phase-2-results-for-belrestotug-dostarlimab-combination-in-nsclc 2025-01-16T05:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-study-aerobic-exercise-shows-dramatic-reduction-in-alzheimer-s-disease-markers 2025-01-16T05:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-study-aerobic-exercise-shows-dramatic-reduction-in-alzheimer-s-disease-markers 2025-01-16T05:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-biotech-surge-forces-us-companies-to-pivot-towards-novel-innovation 2025-01-16T04:24:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-biotech-surge-forces-us-companies-to-pivot-towards-novel-innovation 2025-01-16T04:24:16+00:00 hourly 0.9 https://trial.medpath.com/news/stratum-nutrition-launches-ovolux-a-novel-eggshell-membrane-collagen-ingredient-with-proven-skin-hair-and-nail-benefits 2025-01-16T04:19:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stratum-nutrition-launches-ovolux-a-novel-eggshell-membrane-collagen-ingredient-with-proven-skin-hair-and-nail-benefits 2025-01-16T04:19:29+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-design-challenges-for-pediatric-obesity-navigating-complex-patient-needs-and-scientific-requirements 2025-01-16T03:31:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-design-challenges-for-pediatric-obesity-navigating-complex-patient-needs-and-scientific-requirements 2025-01-16T03:31:06+00:00 hourly 0.9 https://trial.medpath.com/news/ponsegromab-shows-promise-in-reducing-cancer-cachexia-symptoms-in-phase-2-trial 2025-01-16T03:06:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ponsegromab-shows-promise-in-reducing-cancer-cachexia-symptoms-in-phase-2-trial 2025-01-16T03:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-rcc-data-reinforce-efficacy-of-standard-io-tki-doublets-across-imdc-risk-groups 2025-01-16T02:29:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-rcc-data-reinforce-efficacy-of-standard-io-tki-doublets-across-imdc-risk-groups 2025-01-16T02:29:24+00:00 hourly 0.9 https://trial.medpath.com/news/tranexamic-acid-s-limited-impact-on-preventing-postpartum-haemorrhage-after-vaginal-birth 2025-01-16T00:50:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tranexamic-acid-s-limited-impact-on-preventing-postpartum-haemorrhage-after-vaginal-birth 2025-01-16T00:50:37+00:00 hourly 0.9 https://trial.medpath.com/news/jp-morgan-2025-abbvie-s-strategy-with-skyrizi-and-rinvoq-to-compensate-for-humira-s-decline 2025-01-16T00:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jp-morgan-2025-abbvie-s-strategy-with-skyrizi-and-rinvoq-to-compensate-for-humira-s-decline 2025-01-16T00:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-receives-nmpa-breakthrough-therapy-designation-for-ibi343-in-advanced-pancreatic-cancer-treatment 2025-01-16T00:01:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovent-receives-nmpa-breakthrough-therapy-designation-for-ibi343-in-advanced-pancreatic-cancer-treatment 2025-01-16T00:01:06+00:00 hourly 0.9 https://trial.medpath.com/news/eledon-s-tegoprubart-shows-promise-in-functional-cure-for-type-1-diabetes 2025-01-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eledon-s-tegoprubart-shows-promise-in-functional-cure-for-type-1-diabetes 2025-01-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-astrazeneca-s-ultomiris-for-new-use-in-nmosd-treatment 2025-01-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-rejects-astrazeneca-s-ultomiris-for-new-use-in-nmosd-treatment 2025-01-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/incomplete-toxicity-reporting-and-use-of-toxicity-minimizing-language-in-phase-iii-oncology-trials 2025-01-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incomplete-toxicity-reporting-and-use-of-toxicity-minimizing-language-in-phase-iii-oncology-trials 2025-01-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dual-shp2-and-fgfr2-inhibition-shows-promise-in-treatment-resistant-gastric-cancer 2025-01-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-shp2-and-fgfr2-inhibition-shows-promise-in-treatment-resistant-gastric-cancer 2025-01-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/immunitybio-advances-bladder-cancer-treatment-program-with-promising-trial-results 2025-01-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunitybio-advances-bladder-cancer-treatment-program-with-promising-trial-results 2025-01-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/zoledronate-prevents-morphometric-vertebral-fractures-over-10-years 2025-01-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zoledronate-prevents-morphometric-vertebral-fractures-over-10-years 2025-01-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aspirin-does-not-significantly-improve-survival-in-colorectal-cancer-patients-ascolt-study-finds 2025-01-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aspirin-does-not-significantly-improve-survival-in-colorectal-cancer-patients-ascolt-study-finds 2025-01-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/africa-cdc-leads-groundbreaking-mpox-therapeutic-study-with-first-patient-enrollment 2025-01-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/africa-cdc-leads-groundbreaking-mpox-therapeutic-study-with-first-patient-enrollment 2025-01-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/africa-cdc-leads-groundbreaking-mpox-therapeutic-study-with-first-patient-enrollment 2025-01-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/africa-cdc-leads-groundbreaking-mpox-therapeutic-study-with-first-patient-enrollment 2025-01-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-s-soliris-biosimilar-abp-959-shows-promise-in-phase-3-trials-launch-set-for-2025 2025-01-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-s-soliris-biosimilar-abp-959-shows-promise-in-phase-3-trials-launch-set-for-2025 2025-01-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-niktimvo-for-chronic-gvhd-treatment 2025-01-15T23:13:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-niktimvo-for-chronic-gvhd-treatment 2025-01-15T23:13:09+00:00 hourly 0.9 https://trial.medpath.com/news/immunitybio-submits-marketing-authorization-applications-for-anktiva-bcg-in-europe-and-uk 2025-01-15T22:53:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunitybio-submits-marketing-authorization-applications-for-anktiva-bcg-in-europe-and-uk 2025-01-15T22:53:05+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-s-omvoh-earns-fda-approval-for-crohn-s-disease 2025-01-15T22:17:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-s-omvoh-earns-fda-approval-for-crohn-s-disease 2025-01-15T22:17:22+00:00 hourly 0.9 https://trial.medpath.com/news/nivolumab-plus-ipilimumab-shows-promise-in-treating-rare-gu-cancers 2025-01-15T22:09:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nivolumab-plus-ipilimumab-shows-promise-in-treating-rare-gu-cancers 2025-01-15T22:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/liver-cirrhosis-clinical-trial-pipeline-gains-momentum 2025-01-15T21:52:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liver-cirrhosis-clinical-trial-pipeline-gains-momentum 2025-01-15T21:52:38+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-receives-fda-approval-for-crohn-s-disease-treatment 2025-01-15T21:46:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-receives-fda-approval-for-crohn-s-disease-treatment 2025-01-15T21:46:04+00:00 hourly 0.9 https://trial.medpath.com/news/mainstay-medical-announces-positive-outcomes-from-landmark-restore-clinical-trial-of-reactiv8-r 2025-01-15T21:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mainstay-medical-announces-positive-outcomes-from-landmark-restore-clinical-trial-of-reactiv8-r 2025-01-15T21:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/yale-led-study-will-compare-effectiveness-of-iv-ketamine-and-esketamine-nasal-spray 2025-01-15T21:28:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yale-led-study-will-compare-effectiveness-of-iv-ketamine-and-esketamine-nasal-spray 2025-01-15T21:28:57+00:00 hourly 0.9 https://trial.medpath.com/news/novel-drug-shows-promise-in-reducing-dermatomyositis-disease-activity 2025-01-15T21:28:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-drug-shows-promise-in-reducing-dermatomyositis-disease-activity 2025-01-15T21:28:14+00:00 hourly 0.9 https://trial.medpath.com/news/zai-labs-announces-positive-results-in-china-arm-of-phase-iii-cervical-cancer-trial 2025-01-15T20:58:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zai-labs-announces-positive-results-in-china-arm-of-phase-iii-cervical-cancer-trial 2025-01-15T20:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/medipost-expands-in-us-and-canada-plans-us-phase-iii-of-cartistem 2025-01-15T20:45:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medipost-expands-in-us-and-canada-plans-us-phase-iii-of-cartistem 2025-01-15T20:45:21+00:00 hourly 0.9 https://trial.medpath.com/news/alcoholic-hepatitis-pipeline-insights-2024-emerging-therapies-and-market-prospects 2025-01-15T19:58:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alcoholic-hepatitis-pipeline-insights-2024-emerging-therapies-and-market-prospects 2025-01-15T19:58:37+00:00 hourly 0.9 https://trial.medpath.com/news/exploring-the-role-of-psilocybin-in-easing-end-of-life-care 2025-01-15T19:46:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exploring-the-role-of-psilocybin-in-easing-end-of-life-care 2025-01-15T19:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-finding-xenon-gas-could-protect-against-alzheimer-s-disease-leads-to-start-of-clinical-trial 2025-01-15T19:37:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-finding-xenon-gas-could-protect-against-alzheimer-s-disease-leads-to-start-of-clinical-trial 2025-01-15T19:37:11+00:00 hourly 0.9 https://trial.medpath.com/news/vici-health-sciences-expands-cdmo-operations-with-phase-iii-and-commercial-manufacturing-capabilities 2025-01-15T19:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vici-health-sciences-expands-cdmo-operations-with-phase-iii-and-commercial-manufacturing-capabilities 2025-01-15T19:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/gnrh-agonists-show-promise-for-fertility-preservation-in-premenopausal-women-with-breast-cancer 2025-01-15T19:13:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gnrh-agonists-show-promise-for-fertility-preservation-in-premenopausal-women-with-breast-cancer 2025-01-15T19:13:12+00:00 hourly 0.9 https://trial.medpath.com/news/new-cervical-cancer-treatment-approach-offers-hope-for-longer-survival 2025-01-15T19:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-cervical-cancer-treatment-approach-offers-hope-for-longer-survival 2025-01-15T19:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-and-molecular-factors-linked-to-pcr-in-her2-enriched-breast-cancer-treatment 2025-01-15T19:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-and-molecular-factors-linked-to-pcr-in-her2-enriched-breast-cancer-treatment 2025-01-15T19:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-explains-why-it-rejected-vanda-s-stomach-drug-in-late-2024 2025-01-15T18:21:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-explains-why-it-rejected-vanda-s-stomach-drug-in-late-2024 2025-01-15T18:21:45+00:00 hourly 0.9 https://trial.medpath.com/news/silver-bullet-therapeutics-announces-fda-approval-of-pre-market-study 2025-01-15T18:20:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/silver-bullet-therapeutics-announces-fda-approval-of-pre-market-study 2025-01-15T18:20:48+00:00 hourly 0.9 https://trial.medpath.com/news/cybin-launches-strategic-clinical-site-partnerships-to-support-paradigm-a-multinational-phase-3-program 2025-01-15T18:13:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cybin-launches-strategic-clinical-site-partnerships-to-support-paradigm-a-multinational-phase-3-program 2025-01-15T18:13:13+00:00 hourly 0.9 https://trial.medpath.com/news/jazz-pharmaceuticals-to-focus-on-oncology-pipeline-in-2025 2025-01-15T18:13:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jazz-pharmaceuticals-to-focus-on-oncology-pipeline-in-2025 2025-01-15T18:13:02+00:00 hourly 0.9 https://trial.medpath.com/news/tisotumab-vedotin-shows-promising-survival-benefits-in-chinese-patients-with-previously-treated-cervical-cancer 2025-01-15T18:12:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tisotumab-vedotin-shows-promising-survival-benefits-in-chinese-patients-with-previously-treated-cervical-cancer 2025-01-15T18:12:29+00:00 hourly 0.9 https://trial.medpath.com/news/uhnm-recognized-for-leading-role-in-national-stroke-trials 2025-01-15T17:54:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uhnm-recognized-for-leading-role-in-national-stroke-trials 2025-01-15T17:54:34+00:00 hourly 0.9 https://trial.medpath.com/news/national-clinical-trial-offers-new-hope-for-pediatric-leukemia-treatment 2025-01-15T17:46:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/national-clinical-trial-offers-new-hope-for-pediatric-leukemia-treatment 2025-01-15T17:46:48+00:00 hourly 0.9 https://trial.medpath.com/news/inflarx-s-gohibic-receives-european-commission-approval-for-covid-19-ards-treatment 2025-01-15T17:42:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inflarx-s-gohibic-receives-european-commission-approval-for-covid-19-ards-treatment 2025-01-15T17:42:12+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-submits-tar-200-for-fda-review-lykos-therapeutics-board-shakeup 2025-01-15T17:15:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-j-submits-tar-200-for-fda-review-lykos-therapeutics-board-shakeup 2025-01-15T17:15:57+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ind-application-for-novel-monoclonal-antibody-ox40-antagonist-for-atopic-dermatitis 2025-01-15T17:08:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ind-application-for-novel-monoclonal-antibody-ox40-antagonist-for-atopic-dermatitis 2025-01-15T17:08:56+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trials-are-testing-ways-to-prevent-breast-cancer 2025-01-15T17:00:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trials-are-testing-ways-to-prevent-breast-cancer 2025-01-15T17:00:13+00:00 hourly 0.9 https://trial.medpath.com/news/fluoguide-a-s-receives-approval-for-phase-ii-trial-in-head-and-neck-cancer 2025-01-15T16:24:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fluoguide-a-s-receives-approval-for-phase-ii-trial-in-head-and-neck-cancer 2025-01-15T16:24:46+00:00 hourly 0.9 https://trial.medpath.com/news/context-doses-first-subject-in-phase-i-cancer-trial-of-ctim-76 2025-01-15T16:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/context-doses-first-subject-in-phase-i-cancer-trial-of-ctim-76 2025-01-15T16:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/accc-initiative-enhances-care-standards-for-myeloproliferative-neoplasms-across-us-centers 2025-01-15T15:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accc-initiative-enhances-care-standards-for-myeloproliferative-neoplasms-across-us-centers 2025-01-15T15:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-skyrizi-and-rinvoq-gain-market-share-as-company-navigates-post-humira-landscape 2025-01-15T15:30:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-s-skyrizi-and-rinvoq-gain-market-share-as-company-navigates-post-humira-landscape 2025-01-15T15:30:48+00:00 hourly 0.9 https://trial.medpath.com/news/laxxon-medical-announces-positive-pilot-pk-study-results-in-pigs-for-groundbreaking-oral-glp-1-dosage-form 2025-01-15T15:22:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/laxxon-medical-announces-positive-pilot-pk-study-results-in-pigs-for-groundbreaking-oral-glp-1-dosage-form 2025-01-15T15:22:01+00:00 hourly 0.9 https://trial.medpath.com/news/new-drug-application-submitted-to-fda-for-tar-200-in-treating-nmibc 2025-01-15T15:20:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-drug-application-submitted-to-fda-for-tar-200-in-treating-nmibc 2025-01-15T15:20:35+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-executives-address-investor-pressure-and-strategic-focus-at-jpm25 2025-01-15T15:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-executives-address-investor-pressure-and-strategic-focus-at-jpm25 2025-01-15T15:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/laxxon-medical-announces-positive-pilot-pk-study-results-for-groundbreaking-oral-glp-1-dosage-form 2025-01-15T15:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/laxxon-medical-announces-positive-pilot-pk-study-results-for-groundbreaking-oral-glp-1-dosage-form 2025-01-15T15:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/aim-immunotech-advances-multiple-ampligen-clinical-trials-with-major-milestone-updates-for-2025-2026 2025-01-15T15:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aim-immunotech-advances-multiple-ampligen-clinical-trials-with-major-milestone-updates-for-2025-2026 2025-01-15T15:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/fruquintinib-plus-sintilimab-shows-promising-efficacy-in-advanced-renal-cell-carcinoma 2025-01-15T14:55:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fruquintinib-plus-sintilimab-shows-promising-efficacy-in-advanced-renal-cell-carcinoma 2025-01-15T14:55:03+00:00 hourly 0.9 https://trial.medpath.com/news/ivy-brain-tumor-center-expands-global-phase-3-gliofocus-study-to-the-eu-and-additional-us-states 2025-01-15T14:48:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ivy-brain-tumor-center-expands-global-phase-3-gliofocus-study-to-the-eu-and-additional-us-states 2025-01-15T14:48:22+00:00 hourly 0.9 https://trial.medpath.com/news/be-bio-secures-92m-series-c-financing-to-advance-clinical-programs 2025-01-15T14:39:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/be-bio-secures-92m-series-c-financing-to-advance-clinical-programs 2025-01-15T14:39:37+00:00 hourly 0.9 https://trial.medpath.com/news/nextbiomedical-receives-ide-approval-from-fda-for-nexsphere-ftm-an-embolic-microsphere-for-knee-osteoarthritis 2025-01-15T14:36:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nextbiomedical-receives-ide-approval-from-fda-for-nexsphere-ftm-an-embolic-microsphere-for-knee-osteoarthritis 2025-01-15T14:36:15+00:00 hourly 0.9 https://trial.medpath.com/news/phase-2b-clinical-trial-of-ost-her2-shows-promising-results-in-osteosarcoma-treatment 2025-01-15T14:33:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-2b-clinical-trial-of-ost-her2-shows-promising-results-in-osteosarcoma-treatment 2025-01-15T14:33:18+00:00 hourly 0.9 https://trial.medpath.com/news/inflammasome-therapeutics-announces-positive-3-month-clinical-trial-results-for-k8-in-geographic-atrophy 2025-01-15T14:21:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inflammasome-therapeutics-announces-positive-3-month-clinical-trial-results-for-k8-in-geographic-atrophy 2025-01-15T14:21:38+00:00 hourly 0.9 https://trial.medpath.com/news/metformin-shows-promise-in-reducing-non-melanoma-skin-cancer-risk-study-finds 2025-01-15T14:10:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metformin-shows-promise-in-reducing-non-melanoma-skin-cancer-risk-study-finds 2025-01-15T14:10:30+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-data-shows-iptacopan-eases-fatigue-in-c5i-experienced-naive-pnh-patients 2025-01-15T14:08:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-data-shows-iptacopan-eases-fatigue-in-c5i-experienced-naive-pnh-patients 2025-01-15T14:08:05+00:00 hourly 0.9 https://trial.medpath.com/news/denali-and-takeda-open-ftd-grn-clinical-trial-site-at-upenn 2025-01-15T14:04:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/denali-and-takeda-open-ftd-grn-clinical-trial-site-at-upenn 2025-01-15T14:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-of-antimalarial-as-repurposing-drug-for-covid-19 2025-01-15T13:50:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-of-antimalarial-as-repurposing-drug-for-covid-19 2025-01-15T13:50:09+00:00 hourly 0.9 https://trial.medpath.com/news/regulatory-approval-advances-oncolytics-biotech-s-pancreatic-cancer-treatment-study 2025-01-15T13:44:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regulatory-approval-advances-oncolytics-biotech-s-pancreatic-cancer-treatment-study 2025-01-15T13:44:44+00:00 hourly 0.9 https://trial.medpath.com/news/sen-jam-pharmaceutical-announces-preliminary-results-from-phase-2-clinical-trials-of-sjp-002c-for-upper-respiratory-infections-covid-19 2025-01-15T13:31:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sen-jam-pharmaceutical-announces-preliminary-results-from-phase-2-clinical-trials-of-sjp-002c-for-upper-respiratory-infections-covid-19 2025-01-15T13:31:29+00:00 hourly 0.9 https://trial.medpath.com/news/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01 2025-01-15T13:18:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01 2025-01-15T13:18:11+00:00 hourly 0.9 https://trial.medpath.com/news/alzamend-neuro-to-present-at-the-sequire-investor-summit 2025-01-15T13:18:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzamend-neuro-to-present-at-the-sequire-investor-summit 2025-01-15T13:18:06+00:00 hourly 0.9 https://trial.medpath.com/news/durvalumab-shifts-decades-long-soc-as-first-fda-approved-immunotherapy-regimen-in-ls-sclc 2025-01-15T13:12:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/durvalumab-shifts-decades-long-soc-as-first-fda-approved-immunotherapy-regimen-in-ls-sclc 2025-01-15T13:12:26+00:00 hourly 0.9 https://trial.medpath.com/news/lykos-therapeutics-faces-board-resignations-following-fda-rejection 2025-01-15T13:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lykos-therapeutics-faces-board-resignations-following-fda-rejection 2025-01-15T13:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/key-drugs-to-watch-for-community-pharmacy-in-2025 2025-01-15T13:04:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/key-drugs-to-watch-for-community-pharmacy-in-2025 2025-01-15T13:04:10+00:00 hourly 0.9 https://trial.medpath.com/news/owlstone-medical-secures-27-million-in-series-e-financing-round 2025-01-15T12:58:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/owlstone-medical-secures-27-million-in-series-e-financing-round 2025-01-15T12:58:06+00:00 hourly 0.9 https://trial.medpath.com/news/inspector-general-questions-fda-s-accelerated-approval-for-biogen-sarepta-drugs 2025-01-15T12:53:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inspector-general-questions-fda-s-accelerated-approval-for-biogen-sarepta-drugs 2025-01-15T12:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-announces-complete-ban-of-red-dye-no-3-in-food-and-drugs-due-to-cancer-risk 2025-01-15T12:48:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-announces-complete-ban-of-red-dye-no-3-in-food-and-drugs-due-to-cancer-risk 2025-01-15T12:48:21+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-achieves-phase-iii-success-in-skin-cancer-treatment-with-libtayo 2025-01-15T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-achieves-phase-iii-success-in-skin-cancer-treatment-with-libtayo 2025-01-15T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/keros-therapeutics-halts-all-dosing-in-phase-2-tropos-trial-for-pah-due-to-safety-concerns 2025-01-15T12:28:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/keros-therapeutics-halts-all-dosing-in-phase-2-tropos-trial-for-pah-due-to-safety-concerns 2025-01-15T12:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/attralus-announces-enrollment-of-first-patient-in-phase-3-trial-for-the-pan-amyloid-diagnostic-124i-evuzamitide-at-01-for-cardiac-amyloidosis 2025-01-15T12:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/attralus-announces-enrollment-of-first-patient-in-phase-3-trial-for-the-pan-amyloid-diagnostic-124i-evuzamitide-at-01-for-cardiac-amyloidosis 2025-01-15T12:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/brain-q-achieves-ce-mark-for-breakthrough-therapy-in-reducing-post-stroke-disability 2025-01-15T12:17:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brain-q-achieves-ce-mark-for-breakthrough-therapy-in-reducing-post-stroke-disability 2025-01-15T12:17:42+00:00 hourly 0.9 https://trial.medpath.com/news/luye-pharma-initiates-phase-ii-trial-for-cns-drug-ly03015-in-china 2025-01-15T12:07:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/luye-pharma-initiates-phase-ii-trial-for-cns-drug-ly03015-in-china 2025-01-15T12:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/molecular-profiling-shows-promise-in-select-sclc-cases-particularly-for-non-smokers 2025-01-15T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/molecular-profiling-shows-promise-in-select-sclc-cases-particularly-for-non-smokers 2025-01-15T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/blackstone-delays-auction-for-cmax-clinical-trials-amid-accc-divestment-order 2025-01-15T11:52:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blackstone-delays-auction-for-cmax-clinical-trials-amid-accc-divestment-order 2025-01-15T11:52:47+00:00 hourly 0.9 https://trial.medpath.com/news/vanderbilt-cancer-expert-emphasizes-community-centered-approach-to-improve-healthcare-access 2025-01-15T10:11:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vanderbilt-cancer-expert-emphasizes-community-centered-approach-to-improve-healthcare-access 2025-01-15T10:11:59+00:00 hourly 0.9 https://trial.medpath.com/news/vistagen-reports-positive-outcomes-from-phase-iia-cancer-cachexia-trial 2025-01-15T09:25:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vistagen-reports-positive-outcomes-from-phase-iia-cancer-cachexia-trial 2025-01-15T09:25:18+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-43-prevalence-of-long-covid-among-hiv-patients-highlighting-potential-health-risk 2025-01-15T09:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-43-prevalence-of-long-covid-among-hiv-patients-highlighting-potential-health-risk 2025-01-15T09:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/systematic-review-challenges-effectiveness-of-post-hospital-discharge-follow-up-calls 2025-01-15T08:31:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/systematic-review-challenges-effectiveness-of-post-hospital-discharge-follow-up-calls 2025-01-15T08:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/asthma-linked-to-more-severe-and-early-onset-alopecia-areata-large-european-study-finds 2025-01-15T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asthma-linked-to-more-severe-and-early-onset-alopecia-areata-large-european-study-finds 2025-01-15T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/aaps-national-biotechnology-conference-2025-to-showcase-latest-advances-in-biologics-and-advanced-therapies 2025-01-15T08:07:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aaps-national-biotechnology-conference-2025-to-showcase-latest-advances-in-biologics-and-advanced-therapies 2025-01-15T08:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/ai-advances-show-promise-in-early-cancer-detection-and-personalized-treatment-strategies 2025-01-15T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-advances-show-promise-in-early-cancer-detection-and-personalized-treatment-strategies 2025-01-15T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tc-biopharm-initiates-preclinical-studies-for-tcb008-targeting-h5n1-bird-flu 2025-01-15T07:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tc-biopharm-initiates-preclinical-studies-for-tcb008-targeting-h5n1-bird-flu 2025-01-15T07:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/los-angeles-wildfires-devastate-medical-community-at-least-270-physicians-homes-at-risk 2025-01-15T07:32:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/los-angeles-wildfires-devastate-medical-community-at-least-270-physicians-homes-at-risk 2025-01-15T07:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-launches-fda-approved-xt-cdx-test-nationwide-for-comprehensive-solid-tumor-profiling 2025-01-15T07:19:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempus-launches-fda-approved-xt-cdx-test-nationwide-for-comprehensive-solid-tumor-profiling 2025-01-15T07:19:13+00:00 hourly 0.9 https://trial.medpath.com/news/cdmo-industry-forecast-2025-ai-cost-efficiency-and-glp-1-impact-reshape-pharmaceutical-manufacturing 2025-01-15T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdmo-industry-forecast-2025-ai-cost-efficiency-and-glp-1-impact-reshape-pharmaceutical-manufacturing 2025-01-15T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/advancements-in-gastrointestinal-stromal-tumors-treatment-pipeline 2025-01-15T06:48:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancements-in-gastrointestinal-stromal-tumors-treatment-pipeline 2025-01-15T06:48:46+00:00 hourly 0.9 https://trial.medpath.com/news/gensight-biologics-announces-5-year-follow-up-results-for-lumevoq-r-in-lhon-treatment 2025-01-15T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gensight-biologics-announces-5-year-follow-up-results-for-lumevoq-r-in-lhon-treatment 2025-01-15T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/mindbio-updates-on-phase-2b-clinical-trials-and-technological-advances 2025-01-15T06:03:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mindbio-updates-on-phase-2b-clinical-trials-and-technological-advances 2025-01-15T06:03:51+00:00 hourly 0.9 https://trial.medpath.com/news/va-study-reveals-11-of-primary-care-appointments-face-same-day-cancellations 2025-01-15T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/va-study-reveals-11-of-primary-care-appointments-face-same-day-cancellations 2025-01-15T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/digital-health-innovation-bridges-healthcare-access-gap-in-uk-and-nigeria 2025-01-15T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/digital-health-innovation-bridges-healthcare-access-gap-in-uk-and-nigeria 2025-01-15T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5-year-follow-up-of-the-phase-2-optic-study-in-patients-with-chronic-phase-chronic-myeloid-leukemia 2025-01-15T04:57:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/5-year-follow-up-of-the-phase-2-optic-study-in-patients-with-chronic-phase-chronic-myeloid-leukemia 2025-01-15T04:57:56+00:00 hourly 0.9 https://trial.medpath.com/news/afami-cel-approval-and-its-potential-influence-on-the-adoption-of-tcr-therapies 2025-01-15T04:57:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/afami-cel-approval-and-its-potential-influence-on-the-adoption-of-tcr-therapies 2025-01-15T04:57:49+00:00 hourly 0.9 https://trial.medpath.com/news/breast-cancer-index-test-could-enable-personalized-endocrine-therapy-duration-in-hr-breast-cancer 2025-01-15T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breast-cancer-index-test-could-enable-personalized-endocrine-therapy-duration-in-hr-breast-cancer 2025-01-15T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/neuphoria-therapeutics-regains-nasdaq-compliance-amidst-strategic-developments 2025-01-15T03:18:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuphoria-therapeutics-regains-nasdaq-compliance-amidst-strategic-developments 2025-01-15T03:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/supply-chain-innovation-critical-for-106-billion-personalized-medicine-market-growth-by-2029 2025-01-15T03:00:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/supply-chain-innovation-critical-for-106-billion-personalized-medicine-market-growth-by-2029 2025-01-15T03:00:57+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-faces-critical-opportunity-to-transform-healthcare-through-biosimilars-adoption 2025-01-15T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-faces-critical-opportunity-to-transform-healthcare-through-biosimilars-adoption 2025-01-15T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/glaukos-announces-positive-clinical-updates-for-its-idose-sustained-release-procedural-pharmaceutical-platform 2025-01-15T02:34:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glaukos-announces-positive-clinical-updates-for-its-idose-sustained-release-procedural-pharmaceutical-platform 2025-01-15T02:34:20+00:00 hourly 0.9 https://trial.medpath.com/news/vera-therapeutics-advances-with-strategic-licensing-and-promising-clinical-data 2025-01-15T01:44:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vera-therapeutics-advances-with-strategic-licensing-and-promising-clinical-data 2025-01-15T01:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/axcynsis-therapeutics-receives-fda-clearance-for-ind-application-of-at03-65 2025-01-15T01:21:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/axcynsis-therapeutics-receives-fda-clearance-for-ind-application-of-at03-65 2025-01-15T01:21:39+00:00 hourly 0.9 https://trial.medpath.com/news/nuvalent-s-lung-cancer-drug-shows-promise-amid-risks 2025-01-15T00:43:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuvalent-s-lung-cancer-drug-shows-promise-amid-risks 2025-01-15T00:43:45+00:00 hourly 0.9 https://trial.medpath.com/news/springworks-therapeutics-achieves-significant-milestones-and-financial-growth-in-2024 2025-01-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/springworks-therapeutics-achieves-significant-milestones-and-financial-growth-in-2024 2025-01-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/grifols-receives-21-million-grant-for-parkinson-s-biomarker-research 2025-01-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grifols-receives-21-million-grant-for-parkinson-s-biomarker-research 2025-01-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/anlotinib-shows-promise-as-maintenance-therapy-for-es-sclc 2025-01-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anlotinib-shows-promise-as-maintenance-therapy-for-es-sclc 2025-01-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cabaletta-bio-advances-novel-car-t-cell-therapy-for-multiple-sclerosis-into-phase-1-2-trial 2025-01-14T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cabaletta-bio-advances-novel-car-t-cell-therapy-for-multiple-sclerosis-into-phase-1-2-trial 2025-01-14T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-imposes-clinical-hold-on-solid-biosciences-dmd-gene-therapy-following-adverse-event 2025-01-14T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-imposes-clinical-hold-on-solid-biosciences-dmd-gene-therapy-following-adverse-event 2025-01-14T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-advances-hiv-vaccine-trials-in-africa-with-mrna-technology 2025-01-14T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-advances-hiv-vaccine-trials-in-africa-with-mrna-technology 2025-01-14T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-novel-antibiotic-shows-promise-in-treating-drug-resistant-tuberculosis 2025-01-14T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-s-novel-antibiotic-shows-promise-in-treating-drug-resistant-tuberculosis 2025-01-14T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/hepatitis-e-vaccine-proves-effective-with-two-doses-in-sudan-epidemic 2025-01-14T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hepatitis-e-vaccine-proves-effective-with-two-doses-in-sudan-epidemic 2025-01-14T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-novel-antibiotic-shows-promise-in-treating-drug-resistant-tuberculosis 2025-01-14T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-s-novel-antibiotic-shows-promise-in-treating-drug-resistant-tuberculosis 2025-01-14T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/insmed-advances-novel-gene-therapy-for-duchenne-muscular-dystrophy-with-fda-ind-clearance 2025-01-14T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insmed-advances-novel-gene-therapy-for-duchenne-muscular-dystrophy-with-fda-ind-clearance 2025-01-14T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/pds-biotechnology-advances-in-immunotherapy-and-clinical-trials 2025-01-14T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pds-biotechnology-advances-in-immunotherapy-and-clinical-trials 2025-01-14T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-mri-contrast-agent-shows-promise-in-breast-cancer-imaging-clinical-results-to-be-published-in-investigative-radiology 2025-01-14T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-mri-contrast-agent-shows-promise-in-breast-cancer-imaging-clinical-results-to-be-published-in-investigative-radiology 2025-01-14T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/cardiofocus-announces-1-year-eclipse-af-trial-results 2025-01-14T22:58:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cardiofocus-announces-1-year-eclipse-af-trial-results 2025-01-14T22:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/non-small-cell-lung-cancer-clinical-trial-pipeline-sees-significant-growth 2025-01-14T22:31:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/non-small-cell-lung-cancer-clinical-trial-pipeline-sees-significant-growth 2025-01-14T22:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/applied-therapeutics-faces-fda-scrutiny-shareholder-lawsuits-over-clinical-trial-issues 2025-01-14T22:03:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/applied-therapeutics-faces-fda-scrutiny-shareholder-lawsuits-over-clinical-trial-issues 2025-01-14T22:03:06+00:00 hourly 0.9 https://trial.medpath.com/news/current-status-of-neoadjuvant-treatment-before-surgery-in-high-risk-localized-prostate-cancer 2025-01-14T21:15:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/current-status-of-neoadjuvant-treatment-before-surgery-in-high-risk-localized-prostate-cancer 2025-01-14T21:15:04+00:00 hourly 0.9 https://trial.medpath.com/news/icotec-announces-fda-clearance-for-spinal-infection-indication-with-blackarmor-implants 2025-01-14T20:34:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icotec-announces-fda-clearance-for-spinal-infection-indication-with-blackarmor-implants 2025-01-14T20:34:29+00:00 hourly 0.9 https://trial.medpath.com/news/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025 2025-01-14T20:30:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025 2025-01-14T20:30:07+00:00 hourly 0.9 https://trial.medpath.com/news/digital-integrative-medicine-intervention-shows-promise-in-reducing-cancer-treatment-symptoms 2025-01-14T20:28:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/digital-integrative-medicine-intervention-shows-promise-in-reducing-cancer-treatment-symptoms 2025-01-14T20:28:31+00:00 hourly 0.9 https://trial.medpath.com/news/can-a-diabetes-drug-prevent-osteoarthritis-after-acl-tear 2025-01-14T19:58:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/can-a-diabetes-drug-prevent-osteoarthritis-after-acl-tear 2025-01-14T19:58:53+00:00 hourly 0.9 https://trial.medpath.com/news/swtx-announces-2024-preliminary-results-and-2025-goals 2025-01-14T18:53:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/swtx-announces-2024-preliminary-results-and-2025-goals 2025-01-14T18:53:16+00:00 hourly 0.9 https://trial.medpath.com/news/aurinia-pharmaceuticals-reports-strong-q3-2024-financial-results-and-advances-in-biotech-innovations 2025-01-14T18:49:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aurinia-pharmaceuticals-reports-strong-q3-2024-financial-results-and-advances-in-biotech-innovations 2025-01-14T18:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/bladder-tumor-focused-adaptive-radiotherapy-shows-feasibility-in-phase-2-trial 2025-01-14T18:38:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bladder-tumor-focused-adaptive-radiotherapy-shows-feasibility-in-phase-2-trial 2025-01-14T18:38:51+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-s-pharmaceutical-growth-strategy-advances-with-key-pipeline-developments 2025-01-14T18:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-s-pharmaceutical-growth-strategy-advances-with-key-pipeline-developments 2025-01-14T18:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/bio-thera-solutions-announces-phase-i-clinical-study-results-for-bat4406f-in-nmosd-patients 2025-01-14T18:04:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bio-thera-solutions-announces-phase-i-clinical-study-results-for-bat4406f-in-nmosd-patients 2025-01-14T18:04:10+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-defends-maritide-merck-plans-for-keytruda-s-future-and-viking-s-strategic-moves-in-obesity-market 2025-01-14T18:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-defends-maritide-merck-plans-for-keytruda-s-future-and-viking-s-strategic-moves-in-obesity-market 2025-01-14T18:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-s-maritide-aims-to-revolutionize-obesity-treatment-with-monthly-dosing 2025-01-14T17:50:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-s-maritide-aims-to-revolutionize-obesity-treatment-with-monthly-dosing 2025-01-14T17:50:37+00:00 hourly 0.9 https://trial.medpath.com/news/new-cellular-immunotherapy-approach-shows-promise-for-b-cell-lymphoma 2025-01-14T17:34:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-cellular-immunotherapy-approach-shows-promise-for-b-cell-lymphoma 2025-01-14T17:34:15+00:00 hourly 0.9 https://trial.medpath.com/news/essentia-recognized-as-highest-enrolling-site-for-important-study 2025-01-14T17:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/essentia-recognized-as-highest-enrolling-site-for-important-study 2025-01-14T17:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/valbiotis-announces-broad-success-of-phase-ii-iii-study-on-lipridrive 2025-01-14T17:23:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valbiotis-announces-broad-success-of-phase-ii-iii-study-on-lipridrive 2025-01-14T17:23:03+00:00 hourly 0.9 https://trial.medpath.com/news/loncastuximab-tesirine-shows-high-efficacy-in-treating-high-risk-lymphoma-types 2025-01-14T17:16:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/loncastuximab-tesirine-shows-high-efficacy-in-treating-high-risk-lymphoma-types 2025-01-14T17:16:43+00:00 hourly 0.9 https://trial.medpath.com/news/addition-of-brentuximab-vedotin-to-lenalidomide-rituximab-shows-improved-survival-in-relapsed-or-refractory-dlbcl 2025-01-14T17:11:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/addition-of-brentuximab-vedotin-to-lenalidomide-rituximab-shows-improved-survival-in-relapsed-or-refractory-dlbcl 2025-01-14T17:11:17+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-biontech-moderna-and-more-present-pipeline-updates-at-jpm25 2025-01-14T16:49:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-biontech-moderna-and-more-present-pipeline-updates-at-jpm25 2025-01-14T16:49:47+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-s-new-weight-loss-pill-orforglipron-aims-for-approval-by-early-2026 2025-01-14T16:15:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-s-new-weight-loss-pill-orforglipron-aims-for-approval-by-early-2026 2025-01-14T16:15:25+00:00 hourly 0.9 https://trial.medpath.com/news/new-phase-1-data-on-dlx-001-for-patients-with-major-depressive-disorder 2025-01-14T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-phase-1-data-on-dlx-001-for-patients-with-major-depressive-disorder 2025-01-14T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/neurologist-highlights-key-focus-areas-for-migraine-research-and-advocacy-in-2025 2025-01-14T15:43:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurologist-highlights-key-focus-areas-for-migraine-research-and-advocacy-in-2025 2025-01-14T15:43:47+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-clinical-trial-enrolling-to-test-maralixibat-for-cholestasis-related-itch 2025-01-14T15:38:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-clinical-trial-enrolling-to-test-maralixibat-for-cholestasis-related-itch 2025-01-14T15:38:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-510-k-clearance-to-relief-stent-for-vesicoureteral-reflux 2025-01-14T15:25:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-510-k-clearance-to-relief-stent-for-vesicoureteral-reflux 2025-01-14T15:25:24+00:00 hourly 0.9 https://trial.medpath.com/news/key-trials-in-transplant-ineligible-ndmm 2025-01-14T15:24:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/key-trials-in-transplant-ineligible-ndmm 2025-01-14T15:24:11+00:00 hourly 0.9 https://trial.medpath.com/news/fedratinib-for-the-treatment-of-myelofibrosis-a-review-of-clinical-trial-and-real-world-data 2025-01-14T15:24:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fedratinib-for-the-treatment-of-myelofibrosis-a-review-of-clinical-trial-and-real-world-data 2025-01-14T15:24:11+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-type-1-diabetes-treatment-with-islet-cell-transplant 2025-01-14T14:55:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-in-type-1-diabetes-treatment-with-islet-cell-transplant 2025-01-14T14:55:36+00:00 hourly 0.9 https://trial.medpath.com/news/acadia-pharmaceuticals-seeks-eu-approval-for-trofinetide-a-breakthrough-treatment-for-rett-syndrome 2025-01-14T14:25:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acadia-pharmaceuticals-seeks-eu-approval-for-trofinetide-a-breakthrough-treatment-for-rett-syndrome 2025-01-14T14:25:38+00:00 hourly 0.9 https://trial.medpath.com/news/cel-sci-s-multikine-shows-73-survival-rate-in-cancer-study-fda-approves-new-trial 2025-01-14T14:25:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cel-sci-s-multikine-shows-73-survival-rate-in-cancer-study-fda-approves-new-trial 2025-01-14T14:25:36+00:00 hourly 0.9 https://trial.medpath.com/news/lexaria-s-oral-glp-1-drug-shows-47-fewer-side-effects-than-injectable-zepbound 2025-01-14T14:11:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lexaria-s-oral-glp-1-drug-shows-47-fewer-side-effects-than-injectable-zepbound 2025-01-14T14:11:54+00:00 hourly 0.9 https://trial.medpath.com/news/pacbio-and-radboud-umc-unveil-groundbreaking-study-results-using-hifi-long-read-sequencing 2025-01-14T14:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pacbio-and-radboud-umc-unveil-groundbreaking-study-results-using-hifi-long-read-sequencing 2025-01-14T14:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/taiho-oncology-announces-inclusion-of-decitabine-and-cedazuridine-in-nih-precision-medicine-trials 2025-01-14T14:06:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taiho-oncology-announces-inclusion-of-decitabine-and-cedazuridine-in-nih-precision-medicine-trials 2025-01-14T14:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ariceum-therapeutics-225ac-satoreotide-phase-i-ii-clinical-study-in-patients-with-small-cell-lung-cancer-or-merkel-cell-carcinoma 2025-01-14T14:04:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ariceum-therapeutics-225ac-satoreotide-phase-i-ii-clinical-study-in-patients-with-small-cell-lung-cancer-or-merkel-cell-carcinoma 2025-01-14T14:04:49+00:00 hourly 0.9 https://trial.medpath.com/news/sling-therapeutics-announces-positive-topline-results-from-phase-2b-3-trial-of-oral-small-molecule-linsitinib-in-patients-with-thyroid-eye-disease 2025-01-14T14:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sling-therapeutics-announces-positive-topline-results-from-phase-2b-3-trial-of-oral-small-molecule-linsitinib-in-patients-with-thyroid-eye-disease 2025-01-14T14:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/pasithea-expands-phase-1-trial-of-pas-004-to-eastern-europe-with-data-expected-in-q1-2025 2025-01-14T14:00:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pasithea-expands-phase-1-trial-of-pas-004-to-eastern-europe-with-data-expected-in-q1-2025 2025-01-14T14:00:13+00:00 hourly 0.9 https://trial.medpath.com/news/orocidin-advances-towards-clinical-trials-with-new-toxicity-program-for-periodontitis-treatment 2025-01-14T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orocidin-advances-towards-clinical-trials-with-new-toxicity-program-for-periodontitis-treatment 2025-01-14T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/belumosudil-shows-promise-in-treating-chronic-graft-versus-host-disease 2025-01-14T13:50:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belumosudil-shows-promise-in-treating-chronic-graft-versus-host-disease 2025-01-14T13:50:11+00:00 hourly 0.9 https://trial.medpath.com/news/talphera-s-nephro-crrt-study-gains-fda-backing-for-accelerated-patient-enrollment 2025-01-14T13:48:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/talphera-s-nephro-crrt-study-gains-fda-backing-for-accelerated-patient-enrollment 2025-01-14T13:48:26+00:00 hourly 0.9 https://trial.medpath.com/news/visirose-secures-3-million-seed-financing-for-ocular-therapeutics-development 2025-01-14T13:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/visirose-secures-3-million-seed-financing-for-ocular-therapeutics-development 2025-01-14T13:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/merck-accelerates-launch-of-subcutaneous-keytruda 2025-01-14T13:43:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-accelerates-launch-of-subcutaneous-keytruda 2025-01-14T13:43:03+00:00 hourly 0.9 https://trial.medpath.com/news/new-treatment-options-for-kras-associated-cancers-at-roswell-park 2025-01-14T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-treatment-options-for-kras-associated-cancers-at-roswell-park 2025-01-14T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/sen-jam-pharmaceutical-receives-ethics-approval-for-sjp-001-clinical-trial-in-australia 2025-01-14T13:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sen-jam-pharmaceutical-receives-ethics-approval-for-sjp-001-clinical-trial-in-australia 2025-01-14T13:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/ventyx-biosciences-advances-nlrp3-inhibitor-portfolio-with-phase-2-trials 2025-01-14T13:16:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ventyx-biosciences-advances-nlrp3-inhibitor-portfolio-with-phase-2-trials 2025-01-14T13:16:11+00:00 hourly 0.9 https://trial.medpath.com/news/teva-announces-2026-launch-for-night-and-day-olanzapine-long-acting-injectable 2025-01-14T13:10:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teva-announces-2026-launch-for-night-and-day-olanzapine-long-acting-injectable 2025-01-14T13:10:05+00:00 hourly 0.9 https://trial.medpath.com/news/world-s-first-drug-candidate-developed-by-organoid-and-ai-enters-clinical-trials 2025-01-14T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-s-first-drug-candidate-developed-by-organoid-and-ai-enters-clinical-trials 2025-01-14T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-announces-phase-iii-success-for-libtayo-in-skin-cancer-treatment 2025-01-14T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-announces-phase-iii-success-for-libtayo-in-skin-cancer-treatment 2025-01-14T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/immunoforge-advances-in-clinical-trials-for-dmd-cardiomyopathy-and-chronic-myelogenous-leukemia-treatments 2025-01-14T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunoforge-advances-in-clinical-trials-for-dmd-cardiomyopathy-and-chronic-myelogenous-leukemia-treatments 2025-01-14T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-advances-in-obesity-treatment-with-danuglipron-as-kailera-therapeutics-announces-phase-ii-success 2025-01-14T12:57:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-advances-in-obesity-treatment-with-danuglipron-as-kailera-therapeutics-announces-phase-ii-success 2025-01-14T12:57:09+00:00 hourly 0.9 https://trial.medpath.com/news/tg-therapeutics-announces-preliminary-2024-revenue-and-2025-development-milestones 2025-01-14T12:47:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tg-therapeutics-announces-preliminary-2024-revenue-and-2025-development-milestones 2025-01-14T12:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/ocular-therapeutix-shares-sol-r-enrollment-progress-and-next-steps-for-axpaxli-in-npdr 2025-01-14T12:43:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ocular-therapeutix-shares-sol-r-enrollment-progress-and-next-steps-for-axpaxli-in-npdr 2025-01-14T12:43:37+00:00 hourly 0.9 https://trial.medpath.com/news/blueprint-medicines-blu-808-shows-superior-profile-over-third-harmonic-s-thb001-in-kit-inhibitor-race 2025-01-14T12:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blueprint-medicines-blu-808-shows-superior-profile-over-third-harmonic-s-thb001-in-kit-inhibitor-race 2025-01-14T12:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-unveils-strategic-priorities-and-pipeline-progress-at-j-p-morgan-healthcare-conference 2025-01-14T11:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biontech-unveils-strategic-priorities-and-pipeline-progress-at-j-p-morgan-healthcare-conference 2025-01-14T11:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-paige-s-ai-powered-pancancer-detect 2025-01-14T11:43:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-device-designation-to-paige-s-ai-powered-pancancer-detect 2025-01-14T11:43:27+00:00 hourly 0.9 https://trial.medpath.com/news/immuron-announces-travelan-r-clinical-trial-update 2025-01-14T11:42:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immuron-announces-travelan-r-clinical-trial-update 2025-01-14T11:42:47+00:00 hourly 0.9 https://trial.medpath.com/news/intra-arterial-tenecteplase-after-endovascular-recanalisation-in-acute-stroke-patients 2025-01-14T11:39:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intra-arterial-tenecteplase-after-endovascular-recanalisation-in-acute-stroke-patients 2025-01-14T11:39:57+00:00 hourly 0.9 https://trial.medpath.com/news/daiichi-sankyo-acquires-solid-tumour-adc-gatipotuzumab-from-glycotope-for-132-5-million 2025-01-14T11:38:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daiichi-sankyo-acquires-solid-tumour-adc-gatipotuzumab-from-glycotope-for-132-5-million 2025-01-14T11:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/global-rosacea-therapeutics-pipeline-shows-promising-developments 2025-01-14T11:30:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-rosacea-therapeutics-pipeline-shows-promising-developments 2025-01-14T11:30:35+00:00 hourly 0.9 https://trial.medpath.com/news/novel-her2-targeted-therapies-show-promise-in-overcoming-treatment-resistance-in-advanced-breast-cancer 2025-01-14T11:00:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-her2-targeted-therapies-show-promise-in-overcoming-treatment-resistance-in-advanced-breast-cancer 2025-01-14T11:00:03+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-more-aggressive-end-of-life-care-in-cancer-patients-with-icds 2025-01-14T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-more-aggressive-end-of-life-care-in-cancer-patients-with-icds 2025-01-14T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/samsara-vision-reports-positive-intermediate-term-outcomes-for-sing-imt-surgery 2025-01-14T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsara-vision-reports-positive-intermediate-term-outcomes-for-sing-imt-surgery 2025-01-14T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/direct-switch-from-adalimumab-to-tofacitinib-demonstrates-safety-in-psoriatic-arthritis-treatment 2025-01-14T10:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/direct-switch-from-adalimumab-to-tofacitinib-demonstrates-safety-in-psoriatic-arthritis-treatment 2025-01-14T10:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/akero-therapeutics-completes-enrollment-for-phase-3-synchrony-real-world-study-on-efx 2025-01-14T09:16:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akero-therapeutics-completes-enrollment-for-phase-3-synchrony-real-world-study-on-efx 2025-01-14T09:16:39+00:00 hourly 0.9 https://trial.medpath.com/news/bellaseno-successfully-completes-two-clinical-trials-with-novel-resorbable-breast-implants 2025-01-14T09:07:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bellaseno-successfully-completes-two-clinical-trials-with-novel-resorbable-breast-implants 2025-01-14T09:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/survey-reveals-mixed-outlook-for-smes-in-clinical-research-amid-growing-challenges 2025-01-14T08:57:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/survey-reveals-mixed-outlook-for-smes-in-clinical-research-amid-growing-challenges 2025-01-14T08:57:52+00:00 hourly 0.9 https://trial.medpath.com/news/first-participants-randomized-in-askbio-phase-ii-gene-therapy-trial-for-parkinson-s-disease 2025-01-14T08:54:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-participants-randomized-in-askbio-phase-ii-gene-therapy-trial-for-parkinson-s-disease 2025-01-14T08:54:14+00:00 hourly 0.9 https://trial.medpath.com/news/ftc-report-reveals-7-3-billion-price-inflation-scheme-by-major-pbms-on-specialty-generic-drugs 2025-01-14T08:50:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ftc-report-reveals-7-3-billion-price-inflation-scheme-by-major-pbms-on-specialty-generic-drugs 2025-01-14T08:50:21+00:00 hourly 0.9 https://trial.medpath.com/news/novamigra-tx-advances-migraine-therapy-with-fda-s-endorsement-for-accelerated-clinical-development 2025-01-14T08:46:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novamigra-tx-advances-migraine-therapy-with-fda-s-endorsement-for-accelerated-clinical-development 2025-01-14T08:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/pulsesight-therapeutics-initiates-clinical-plan-for-pst-611-in-dry-amd-geographic-atrophy-treatment 2025-01-14T08:31:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pulsesight-therapeutics-initiates-clinical-plan-for-pst-611-in-dry-amd-geographic-atrophy-treatment 2025-01-14T08:31:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-unveils-mandatory-front-of-package-nutrition-info-labeling-initiative-to-combat-chronic-disease 2025-01-14T08:02:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-unveils-mandatory-front-of-package-nutrition-info-labeling-initiative-to-combat-chronic-disease 2025-01-14T08:02:41+00:00 hourly 0.9 https://trial.medpath.com/news/c4-therapeutics-advances-key-clinical-trials-towards-2025-milestones 2025-01-14T07:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/c4-therapeutics-advances-key-clinical-trials-towards-2025-milestones 2025-01-14T07:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/immuneonco-initiates-phase-1b-2-trial-of-novel-bispecific-antibody-for-advanced-nsclc-in-china 2025-01-14T07:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immuneonco-initiates-phase-1b-2-trial-of-novel-bispecific-antibody-for-advanced-nsclc-in-china 2025-01-14T07:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-to-acquire-scorpion-therapeutics-mutant-selective-pi3ka-inhibitor-program 2025-01-14T06:43:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lilly-to-acquire-scorpion-therapeutics-mutant-selective-pi3ka-inhibitor-program 2025-01-14T06:43:43+00:00 hourly 0.9 https://trial.medpath.com/news/santhera-s-agamree-r-receives-positive-recommendation-for-dmd-treatment-in-scotland 2025-01-14T06:35:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/santhera-s-agamree-r-receives-positive-recommendation-for-dmd-treatment-in-scotland 2025-01-14T06:35:18+00:00 hourly 0.9 https://trial.medpath.com/news/final-patient-completes-treatment-in-irlab-s-phase-iib-study-for-parkinson-s-disease-drug-pirepemat 2025-01-14T06:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/final-patient-completes-treatment-in-irlab-s-phase-iib-study-for-parkinson-s-disease-drug-pirepemat 2025-01-14T06:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/uspstf-updates-osteoporosis-screening-guidelines-recommends-dxa-testing-for-women-65-and-older 2025-01-14T06:19:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uspstf-updates-osteoporosis-screening-guidelines-recommends-dxa-testing-for-women-65-and-older 2025-01-14T06:19:01+00:00 hourly 0.9 https://trial.medpath.com/news/arcellx-s-car-t-therapy-shows-superior-efficacy-in-multiple-myeloma-treatment-including-challenging-extramedullary-disease 2025-01-14T06:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arcellx-s-car-t-therapy-shows-superior-efficacy-in-multiple-myeloma-treatment-including-challenging-extramedullary-disease 2025-01-14T06:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-high-public-willingness-to-fund-dmd-treatment-through-taxes-despite-no-personal-benefit 2025-01-14T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-high-public-willingness-to-fund-dmd-treatment-through-taxes-despite-no-personal-benefit 2025-01-14T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/biotalys-advances-towards-european-approval-for-evoca-biofungicide 2025-01-14T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotalys-advances-towards-european-approval-for-evoca-biofungicide 2025-01-14T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/experts-address-key-challenges-in-implementation-of-tumor-agnostic-therapies-and-genetic-testing 2025-01-14T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experts-address-key-challenges-in-implementation-of-tumor-agnostic-therapies-and-genetic-testing 2025-01-14T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-vaccines-show-promise-as-h5n1-avian-influenza-cases-rise-in-us-cattle-and-humans 2025-01-14T05:42:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrna-vaccines-show-promise-as-h5n1-avian-influenza-cases-rise-in-us-cattle-and-humans 2025-01-14T05:42:27+00:00 hourly 0.9 https://trial.medpath.com/news/vaxart-receives-favorable-dsmb-review-for-covid-19-phase-2b-trial-sentinel-cohort 2025-01-14T05:09:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaxart-receives-favorable-dsmb-review-for-covid-19-phase-2b-trial-sentinel-cohort 2025-01-14T05:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/pheno-therapeutics-receives-mhra-approval-for-first-in-human-trial-of-ms-therapeutic-ptd802 2025-01-14T04:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pheno-therapeutics-receives-mhra-approval-for-first-in-human-trial-of-ms-therapeutic-ptd802 2025-01-14T04:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/nih-study-links-sars-cov-2-infection-to-increased-me-cfs-cases 2025-01-14T04:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-study-links-sars-cov-2-infection-to-increased-me-cfs-cases 2025-01-14T04:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-links-moderately-high-calcium-intake-to-increased-eczema-risk-in-specific-populations 2025-01-14T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-links-moderately-high-calcium-intake-to-increased-eczema-risk-in-specific-populations 2025-01-14T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sillajen-s-anticancer-drug-studies-to-be-featured-at-aacr-2025 2025-01-14T02:25:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sillajen-s-anticancer-drug-studies-to-be-featured-at-aacr-2025 2025-01-14T02:25:33+00:00 hourly 0.9 https://trial.medpath.com/news/evoxac-improves-dry-mouth-symptoms-in-sjogren-s-syndrome-patients 2025-01-14T02:24:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evoxac-improves-dry-mouth-symptoms-in-sjogren-s-syndrome-patients 2025-01-14T02:24:39+00:00 hourly 0.9 https://trial.medpath.com/news/cms-initiates-national-coverage-analysis-for-renal-denervation-treatment-of-hypertension 2025-01-14T02:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cms-initiates-national-coverage-analysis-for-renal-denervation-treatment-of-hypertension 2025-01-14T02:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/phio-pharmaceuticals-reports-encouraging-outcomes-from-second-cohort-in-ph-762-clinical-study 2025-01-14T01:14:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phio-pharmaceuticals-reports-encouraging-outcomes-from-second-cohort-in-ph-762-clinical-study 2025-01-14T01:14:47+00:00 hourly 0.9 https://trial.medpath.com/news/bridgebio-pharma-receives-optimistic-buy-recommendation-amid-promising-drug-developments 2025-01-14T01:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bridgebio-pharma-receives-optimistic-buy-recommendation-amid-promising-drug-developments 2025-01-14T01:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-reports-3-2-billion-in-2024-revenue-submits-three-mrna-products-for-regulatory-approval 2025-01-14T00:47:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-reports-3-2-billion-in-2024-revenue-submits-three-mrna-products-for-regulatory-approval 2025-01-14T00:47:59+00:00 hourly 0.9 https://trial.medpath.com/news/eculizumab-demonstrates-efficacy-in-thymoma-associated-myasthenia-gravis-treatment 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eculizumab-demonstrates-efficacy-in-thymoma-associated-myasthenia-gravis-treatment 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-secures-option-on-sosei-heptares-schizophrenia-therapies-in-eur755m-deal 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boehringer-ingelheim-secures-option-on-sosei-heptares-schizophrenia-therapies-in-eur755m-deal 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/integrated-care-shows-superiority-in-smoking-cessation-among-lung-cancer-screening-participants 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/integrated-care-shows-superiority-in-smoking-cessation-among-lung-cancer-screening-participants 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/integrated-care-shows-superiority-in-smoking-cessation-among-lung-cancer-screening-participants 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/integrated-care-shows-superiority-in-smoking-cessation-among-lung-cancer-screening-participants 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tranexamic-acid-s-limited-efficacy-in-reducing-bleeding-for-hematological-malignancies-patients 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tranexamic-acid-s-limited-efficacy-in-reducing-bleeding-for-hematological-malignancies-patients 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/the-demodex-blepharitis-patient-journey-with-xdemvy-r 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-demodex-blepharitis-patient-journey-with-xdemvy-r 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-biologics-license-application-for-subcutaneous-maintenance-dosing-of-leqembi 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-biologics-license-application-for-subcutaneous-maintenance-dosing-of-leqembi 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-1-trial-shows-promise-for-sitravatinib-nivolumab-ipilimumab-combination-in-advanced-renal-cell-carcinoma 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-1-trial-shows-promise-for-sitravatinib-nivolumab-ipilimumab-combination-in-advanced-renal-cell-carcinoma 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-secures-option-on-sosei-heptares-schizophrenia-therapies-in-eur755m-deal 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boehringer-ingelheim-secures-option-on-sosei-heptares-schizophrenia-therapies-in-eur755m-deal 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tak-071-shows-mixed-results-in-parkinson-s-disease-trial-cognitive-benefits-observed-despite-missing-primary-endpoint 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tak-071-shows-mixed-results-in-parkinson-s-disease-trial-cognitive-benefits-observed-despite-missing-primary-endpoint 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-bms-s-krazati-for-colorectal-cancer-treatment 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-bms-s-krazati-for-colorectal-cancer-treatment 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-sharpens-focus-on-immunology-and-gene-therapy-with-ambitious-pipeline-expansion 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-sharpens-focus-on-immunology-and-gene-therapy-with-ambitious-pipeline-expansion 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-xinnate-s-tcp-25-for-epidermolysis-bullosa-treatment 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-xinnate-s-tcp-25-for-epidermolysis-bullosa-treatment 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-discontinues-phase-3-trial-of-sabatolimab-for-myelodysplastic-syndromes 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-discontinues-phase-3-trial-of-sabatolimab-for-myelodysplastic-syndromes 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/betterlife-pharma-secures-uspto-patent-for-non-hallucinogenic-lsd-derivative-betr-001 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/betterlife-pharma-secures-uspto-patent-for-non-hallucinogenic-lsd-derivative-betr-001 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ema-recommends-novartis-meningitis-b-vaccine-for-approval 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-recommends-novartis-meningitis-b-vaccine-for-approval 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/psilocybin-assisted-therapy-shows-promise-in-altering-personality-traits-for-alcohol-use-disorder-treatment 2025-01-13T23:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psilocybin-assisted-therapy-shows-promise-in-altering-personality-traits-for-alcohol-use-disorder-treatment 2025-01-13T23:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/pooled-analysis-shows-improved-os-outcomes-with-ibrutinib-plus-venetoclax-in-cll-patients 2025-01-13T22:40:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pooled-analysis-shows-improved-os-outcomes-with-ibrutinib-plus-venetoclax-in-cll-patients 2025-01-13T22:40:28+00:00 hourly 0.9 https://trial.medpath.com/news/ultrasound-renal-denervation-a-new-hope-for-resistant-hypertension 2025-01-13T22:24:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ultrasound-renal-denervation-a-new-hope-for-resistant-hypertension 2025-01-13T22:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/rallybio-s-swot-analysis-rare-disease-biotech-stock-faces-pivotal-year 2025-01-13T22:19:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rallybio-s-swot-analysis-rare-disease-biotech-stock-faces-pivotal-year 2025-01-13T22:19:03+00:00 hourly 0.9 https://trial.medpath.com/news/neonc-technologies-pioneers-nasal-brain-delivery-system-for-glioblastoma-treatment 2025-01-13T20:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neonc-technologies-pioneers-nasal-brain-delivery-system-for-glioblastoma-treatment 2025-01-13T20:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-suggests-omitting-axillary-surgery-may-not-compromise-survival-in-early-stage-breast-cancer-patients 2025-01-13T20:30:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-suggests-omitting-axillary-surgery-may-not-compromise-survival-in-early-stage-breast-cancer-patients 2025-01-13T20:30:27+00:00 hourly 0.9 https://trial.medpath.com/news/study-evaluates-telisotuzumab-adizutecan-for-gastric-gej-cancer-treatment 2025-01-13T20:03:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-evaluates-telisotuzumab-adizutecan-for-gastric-gej-cancer-treatment 2025-01-13T20:03:09+00:00 hourly 0.9 https://trial.medpath.com/news/theravac-biologics-partners-with-perceiv-ai-to-optimize-clinical-trials 2025-01-13T20:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theravac-biologics-partners-with-perceiv-ai-to-optimize-clinical-trials 2025-01-13T20:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sarepta-therapeutics-receives-buy-rating-due-to-strong-elevidys-launch-and-promising-pipeline 2025-01-13T19:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sarepta-therapeutics-receives-buy-rating-due-to-strong-elevidys-launch-and-promising-pipeline 2025-01-13T19:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/bausch-lomb-acquires-whitecap-biosciences-to-advance-glaucoma-and-geographic-atrophy-treatments 2025-01-13T18:54:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bausch-lomb-acquires-whitecap-biosciences-to-advance-glaucoma-and-geographic-atrophy-treatments 2025-01-13T18:54:15+00:00 hourly 0.9 https://trial.medpath.com/news/northwestern-s-dr-jennifer-jao-to-co-chair-pre-eminent-aids-clinical-trials-network 2025-01-13T18:51:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/northwestern-s-dr-jennifer-jao-to-co-chair-pre-eminent-aids-clinical-trials-network 2025-01-13T18:51:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-nda-for-3-month-leuprolide-mesylate-formulation-for-advanced-prostate-cancer 2025-01-13T18:36:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-nda-for-3-month-leuprolide-mesylate-formulation-for-advanced-prostate-cancer 2025-01-13T18:36:25+00:00 hourly 0.9 https://trial.medpath.com/news/myocardial-infarction-clinical-trial-pipeline-shows-promising-advances 2025-01-13T18:35:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/myocardial-infarction-clinical-trial-pipeline-shows-promising-advances 2025-01-13T18:35:53+00:00 hourly 0.9 https://trial.medpath.com/news/onera-s-validation-trial-of-home-polysomnography-sleep-device-succeeds 2025-01-13T17:47:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onera-s-validation-trial-of-home-polysomnography-sleep-device-succeeds 2025-01-13T17:47:20+00:00 hourly 0.9 https://trial.medpath.com/news/phio-pharmaceuticals-stock-surges-following-promising-cancer-treatment-results 2025-01-13T17:24:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phio-pharmaceuticals-stock-surges-following-promising-cancer-treatment-results 2025-01-13T17:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/pdufa-date-set-for-neffy-1-mg-for-children-weighing-33-lbs-or-more 2025-01-13T17:09:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pdufa-date-set-for-neffy-1-mg-for-children-weighing-33-lbs-or-more 2025-01-13T17:09:37+00:00 hourly 0.9 https://trial.medpath.com/news/load703-receives-fda-fast-track-designation-for-pancreatic-cancer 2025-01-13T17:06:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/load703-receives-fda-fast-track-designation-for-pancreatic-cancer 2025-01-13T17:06:17+00:00 hourly 0.9 https://trial.medpath.com/news/first-blood-center-receives-full-fda-approval-for-convalescent-plasma-treatment 2025-01-13T17:03:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-blood-center-receives-full-fda-approval-for-convalescent-plasma-treatment 2025-01-13T17:03:17+00:00 hourly 0.9 https://trial.medpath.com/news/inquis-medical-completes-enrollment-in-ide-study-of-thrombectomy-system 2025-01-13T16:52:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inquis-medical-completes-enrollment-in-ide-study-of-thrombectomy-system 2025-01-13T16:52:30+00:00 hourly 0.9 https://trial.medpath.com/news/rise-therapeutics-receives-fda-ind-clearance-to-initiate-clinical-testing-of-r-5780-in-cancer 2025-01-13T16:44:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rise-therapeutics-receives-fda-ind-clearance-to-initiate-clinical-testing-of-r-5780-in-cancer 2025-01-13T16:44:35+00:00 hourly 0.9 https://trial.medpath.com/news/madrigal-pharmaceuticals-announces-preliminary-fourth-quarter-and-full-year-2024-financial-results 2025-01-13T16:31:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/madrigal-pharmaceuticals-announces-preliminary-fourth-quarter-and-full-year-2024-financial-results 2025-01-13T16:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/step-2-trial-of-cervical-cancer-screening-interventions-joins-the-nih-collaboratory 2025-01-13T16:21:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/step-2-trial-of-cervical-cancer-screening-interventions-joins-the-nih-collaboratory 2025-01-13T16:21:45+00:00 hourly 0.9 https://trial.medpath.com/news/alny-announces-preliminary-2024-results-and-2025-outlook 2025-01-13T16:18:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alny-announces-preliminary-2024-results-and-2025-outlook 2025-01-13T16:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/ashvattha-therapeutics-announces-50-million-financing-extension-and-interim-phase-2-ophthalmology-trial-results 2025-01-13T16:17:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ashvattha-therapeutics-announces-50-million-financing-extension-and-interim-phase-2-ophthalmology-trial-results 2025-01-13T16:17:35+00:00 hourly 0.9 https://trial.medpath.com/news/bridgebio-announces-progress-in-clinical-trials-and-2025-milestones 2025-01-13T16:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bridgebio-announces-progress-in-clinical-trials-and-2025-milestones 2025-01-13T16:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/efficacy-and-safety-of-zihua-wenfei-zhisou-granule-in-treating-postinfectious-cough 2025-01-13T15:50:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/efficacy-and-safety-of-zihua-wenfei-zhisou-granule-in-treating-postinfectious-cough 2025-01-13T15:50:15+00:00 hourly 0.9 https://trial.medpath.com/news/morgan-lewis-advises-ankyra-therapeutics-on-expanded-collaboration-with-johnson-johnson 2025-01-13T15:06:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/morgan-lewis-advises-ankyra-therapeutics-on-expanded-collaboration-with-johnson-johnson 2025-01-13T15:06:25+00:00 hourly 0.9 https://trial.medpath.com/news/karyopharm-announces-preliminary-unaudited-2024-revenue-and-2025-objectives 2025-01-13T14:59:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/karyopharm-announces-preliminary-unaudited-2024-revenue-and-2025-objectives 2025-01-13T14:59:48+00:00 hourly 0.9 https://trial.medpath.com/news/simcere-zaiming-and-abbvie-partner-to-develop-novel-trispecific-antibody-for-multiple-myeloma 2025-01-13T14:49:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/simcere-zaiming-and-abbvie-partner-to-develop-novel-trispecific-antibody-for-multiple-myeloma 2025-01-13T14:49:55+00:00 hourly 0.9 https://trial.medpath.com/news/treatment-selection-criteria-evolves-for-metastatic-hormone-sensitive-prostate-cancer-expert-insights 2025-01-13T14:45:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/treatment-selection-criteria-evolves-for-metastatic-hormone-sensitive-prostate-cancer-expert-insights 2025-01-13T14:45:47+00:00 hourly 0.9 https://trial.medpath.com/news/positive-outlook-for-akero-therapeutics-based-on-promising-clinical-trial-developments 2025-01-13T14:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/positive-outlook-for-akero-therapeutics-based-on-promising-clinical-trial-developments 2025-01-13T14:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/astria-therapeutics-announces-design-of-alpha-orbit-pivotal-phase-3-trial-of-navenibart-in-hae 2025-01-13T14:35:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astria-therapeutics-announces-design-of-alpha-orbit-pivotal-phase-3-trial-of-navenibart-in-hae 2025-01-13T14:35:21+00:00 hourly 0.9 https://trial.medpath.com/news/positive-first-in-human-data-for-nim-1324-in-systemic-lupus-erythematosus-treatment-announced 2025-01-13T14:35:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/positive-first-in-human-data-for-nim-1324-in-systemic-lupus-erythematosus-treatment-announced 2025-01-13T14:35:20+00:00 hourly 0.9 https://trial.medpath.com/news/edgewise-therapeutics-inc-ewtx-announces-2025-priorities-and-2024-achievements 2025-01-13T14:25:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/edgewise-therapeutics-inc-ewtx-announces-2025-priorities-and-2024-achievements 2025-01-13T14:25:41+00:00 hourly 0.9 https://trial.medpath.com/news/biomea-fusion-shifts-focus-to-diabetes-and-obesity-medicines 2025-01-13T14:04:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomea-fusion-shifts-focus-to-diabetes-and-obesity-medicines 2025-01-13T14:04:41+00:00 hourly 0.9 https://trial.medpath.com/news/ptc-therapeutics-updates-on-commercial-performance-and-r-d-pipeline 2025-01-13T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ptc-therapeutics-updates-on-commercial-performance-and-r-d-pipeline 2025-01-13T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/geovax-advances-next-generation-covid-19-vaccine-with-promising-clinical-trial-results 2025-01-13T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geovax-advances-next-generation-covid-19-vaccine-with-promising-clinical-trial-results 2025-01-13T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/onchilles-expands-leadership-team-to-advance-first-in-class-cancer-therapies 2025-01-13T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onchilles-expands-leadership-team-to-advance-first-in-class-cancer-therapies 2025-01-13T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/geographic-disparities-ai-an-communities-face-5x-greater-distance-to-lung-cancer-screening-centers 2025-01-13T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geographic-disparities-ai-an-communities-face-5x-greater-distance-to-lung-cancer-screening-centers 2025-01-13T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cybin-inc-achieves-breakthroughs-in-mental-health-treatment 2025-01-13T13:57:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cybin-inc-achieves-breakthroughs-in-mental-health-treatment 2025-01-13T13:57:06+00:00 hourly 0.9 https://trial.medpath.com/news/tarsus-pharmaceuticals-advances-tp-04-for-ocular-rosacea-treatment-and-updates-on-xdemvy-launch 2025-01-13T13:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tarsus-pharmaceuticals-advances-tp-04-for-ocular-rosacea-treatment-and-updates-on-xdemvy-launch 2025-01-13T13:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/cogent-biosciences-sets-key-2025-milestones-for-drug-trials 2025-01-13T13:55:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cogent-biosciences-sets-key-2025-milestones-for-drug-trials 2025-01-13T13:55:30+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-pharma-reports-positive-results-from-c-post-trial-with-libtayo 2025-01-13T13:54:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-pharma-reports-positive-results-from-c-post-trial-with-libtayo 2025-01-13T13:54:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-feasibility-study-with-seastar-medical-s-selective-cytopheretic-device-in-adults-with-cardiorenal-syndrome 2025-01-13T13:49:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-feasibility-study-with-seastar-medical-s-selective-cytopheretic-device-in-adults-with-cardiorenal-syndrome 2025-01-13T13:49:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-spinogenix-s-spg601-for-treatment-of-fragile-x-syndrome 2025-01-13T13:38:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-spinogenix-s-spg601-for-treatment-of-fragile-x-syndrome 2025-01-13T13:38:30+00:00 hourly 0.9 https://trial.medpath.com/news/adaptimmune-receives-u-s-fda-breakthrough-therapy-designation-for-lete-cel 2025-01-13T13:34:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adaptimmune-receives-u-s-fda-breakthrough-therapy-designation-for-lete-cel 2025-01-13T13:34:45+00:00 hourly 0.9 https://trial.medpath.com/news/springworks-therapeutics-anticipates-61-5-million-in-ogsiveo-revenue-for-q4 2025-01-13T13:30:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/springworks-therapeutics-anticipates-61-5-million-in-ogsiveo-revenue-for-q4 2025-01-13T13:30:57+00:00 hourly 0.9 https://trial.medpath.com/news/arbutus-biopharma-advances-towards-functional-cure-for-chronic-hepatitis-b-with-phase-2b-clinical-trial 2025-01-13T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arbutus-biopharma-advances-towards-functional-cure-for-chronic-hepatitis-b-with-phase-2b-clinical-trial 2025-01-13T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/annexon-sets-sights-on-2025-as-a-breakthrough-year-with-key-clinical-milestones 2025-01-13T13:27:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/annexon-sets-sights-on-2025-as-a-breakthrough-year-with-key-clinical-milestones 2025-01-13T13:27:25+00:00 hourly 0.9 https://trial.medpath.com/news/candel-therapeutics-highlights-strong-pipeline-momentum-and-key-value-drivers-for-2025 2025-01-13T13:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/candel-therapeutics-highlights-strong-pipeline-momentum-and-key-value-drivers-for-2025 2025-01-13T13:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/89bio-completes-phase-3-trial-enrollment-fortifies-position-with-440m-cash-reserve 2025-01-13T13:25:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/89bio-completes-phase-3-trial-enrollment-fortifies-position-with-440m-cash-reserve 2025-01-13T13:25:45+00:00 hourly 0.9 https://trial.medpath.com/news/oric-pharmaceuticals-reports-early-phase-1b-data-for-oric-944-and-outlines-2024-achievements-and-future-milestones 2025-01-13T13:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oric-pharmaceuticals-reports-early-phase-1b-data-for-oric-944-and-outlines-2024-achievements-and-future-milestones 2025-01-13T13:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/werewolf-therapeutics-outlines-2025-strategic-outlook-and-anticipated-milestones 2025-01-13T13:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/werewolf-therapeutics-outlines-2025-strategic-outlook-and-anticipated-milestones 2025-01-13T13:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/protara-therapeutics-announces-2025-milestones-and-recent-updates 2025-01-13T13:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protara-therapeutics-announces-2025-milestones-and-recent-updates 2025-01-13T13:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/cabaletta-bio-outlines-strategic-priorities-and-anticipated-key-milestones-for-2025 2025-01-13T13:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cabaletta-bio-outlines-strategic-priorities-and-anticipated-key-milestones-for-2025 2025-01-13T13:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/prodeon-medical-completes-enrollment-for-expander-2-pivotal-trial 2025-01-13T13:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prodeon-medical-completes-enrollment-for-expander-2-pivotal-trial 2025-01-13T13:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/alector-highlights-2025-strategic-priorities-and-recent-progress-in-neurodegenerative-disease-therapies 2025-01-13T13:20:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alector-highlights-2025-strategic-priorities-and-recent-progress-in-neurodegenerative-disease-therapies 2025-01-13T13:20:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-ips-heart-s-givi-mpcs-for-becker-muscular-dystrophy 2025-01-13T13:18:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-ips-heart-s-givi-mpcs-for-becker-muscular-dystrophy 2025-01-13T13:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-pharmaceuticals-poised-for-growth-with-new-drug-launches-and-underappreciated-opportunities 2025-01-13T13:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertex-pharmaceuticals-poised-for-growth-with-new-drug-launches-and-underappreciated-opportunities 2025-01-13T13:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/akebia-s-vafseo-now-available-in-us-with-nearly-complete-dialysis-center-coverage-for-ckd-anemia-treatment 2025-01-13T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akebia-s-vafseo-now-available-in-us-with-nearly-complete-dialysis-center-coverage-for-ckd-anemia-treatment 2025-01-13T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ionis-pharmaceuticals-advances-neurological-and-cardiovascular-therapies-with-new-clinical-trials-and-fda-approvals 2025-01-13T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ionis-pharmaceuticals-advances-neurological-and-cardiovascular-therapies-with-new-clinical-trials-and-fda-approvals 2025-01-13T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/immunome-advances-cancer-pipeline-with-key-updates 2025-01-13T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunome-advances-cancer-pipeline-with-key-updates 2025-01-13T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/calidi-biotherapeutics-to-present-breakthrough-cancer-treatment-data-at-aacr-annual-meeting 2025-01-13T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/calidi-biotherapeutics-to-present-breakthrough-cancer-treatment-data-at-aacr-annual-meeting 2025-01-13T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novocure-reports-revenue-growth-and-fda-approvals-in-2024 2025-01-13T12:55:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novocure-reports-revenue-growth-and-fda-approvals-in-2024 2025-01-13T12:55:45+00:00 hourly 0.9 https://trial.medpath.com/news/new-phase-iib-iii-clinical-data-shows-over-three-years-of-continuous-treatment-with-blarcamesine-benefits-early-alzheimers-disease-patients 2025-01-13T12:43:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-phase-iib-iii-clinical-data-shows-over-three-years-of-continuous-treatment-with-blarcamesine-benefits-early-alzheimers-disease-patients 2025-01-13T12:43:33+00:00 hourly 0.9 https://trial.medpath.com/news/verve-therapeutics-announces-anticipated-2025-milestones-for-gene-editing-programs 2025-01-13T12:40:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verve-therapeutics-announces-anticipated-2025-milestones-for-gene-editing-programs 2025-01-13T12:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/global-neurological-biomarkers-market-set-to-triple-to-31-82-billion-by-2034 2025-01-13T12:38:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-neurological-biomarkers-market-set-to-triple-to-31-82-billion-by-2034 2025-01-13T12:38:46+00:00 hourly 0.9 https://trial.medpath.com/news/icecure-medical-reports-42-increase-in-prosense-sales-for-2024-in-north-america 2025-01-13T12:35:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icecure-medical-reports-42-increase-in-prosense-sales-for-2024-in-north-america 2025-01-13T12:35:30+00:00 hourly 0.9 https://trial.medpath.com/news/x4-pharmaceuticals-and-norgine-enter-into-exclusive-licensing-agreement 2025-01-13T12:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/x4-pharmaceuticals-and-norgine-enter-into-exclusive-licensing-agreement 2025-01-13T12:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/voyageur-begins-human-testing-for-innovative-barium-contrast-product-line 2025-01-13T12:33:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/voyageur-begins-human-testing-for-innovative-barium-contrast-product-line 2025-01-13T12:33:02+00:00 hourly 0.9 https://trial.medpath.com/news/verastem-oncology-announces-debt-refinancing-and-equity-investment 2025-01-13T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verastem-oncology-announces-debt-refinancing-and-equity-investment 2025-01-13T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/foghorn-therapeutics-advances-in-cancer-treatment-with-innovative-programs 2025-01-13T12:24:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/foghorn-therapeutics-advances-in-cancer-treatment-with-innovative-programs 2025-01-13T12:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/syndax-pharmaceuticals-highlights-key-achievements-and-future-milestones-at-j-p-morgan-healthcare-conference 2025-01-13T12:23:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/syndax-pharmaceuticals-highlights-key-achievements-and-future-milestones-at-j-p-morgan-healthcare-conference 2025-01-13T12:23:24+00:00 hourly 0.9 https://trial.medpath.com/news/fecal-transplants-may-help-people-who-have-diabetes-gut-issues-study-says 2025-01-13T12:22:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fecal-transplants-may-help-people-who-have-diabetes-gut-issues-study-says 2025-01-13T12:22:16+00:00 hourly 0.9 https://trial.medpath.com/news/eyepoint-announces-2025-development-milestones-and-company-updates 2025-01-13T12:22:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eyepoint-announces-2025-development-milestones-and-company-updates 2025-01-13T12:22:08+00:00 hourly 0.9 https://trial.medpath.com/news/cartesian-therapeutics-advances-mrna-cell-therapies-for-autoimmune-diseases 2025-01-13T12:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cartesian-therapeutics-advances-mrna-cell-therapies-for-autoimmune-diseases 2025-01-13T12:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/eledon-pharmaceuticals-achieves-key-milestones-and-sets-2025-goals 2025-01-13T12:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eledon-pharmaceuticals-achieves-key-milestones-and-sets-2025-goals 2025-01-13T12:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/fractyl-health-announces-positive-initial-clinical-results-for-weight-maintenance-post-glp-1-discontinuation 2025-01-13T12:15:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fractyl-health-announces-positive-initial-clinical-results-for-weight-maintenance-post-glp-1-discontinuation 2025-01-13T12:15:37+00:00 hourly 0.9 https://trial.medpath.com/news/study-finds-deep-brain-stimulation-enhances-mental-flexibility-in-mental-illness 2025-01-13T12:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-finds-deep-brain-stimulation-enhances-mental-flexibility-in-mental-illness 2025-01-13T12:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/bicycle-therapeutics-cancer-drug-shows-impressive-65-response-rate-in-phase-1-trial 2025-01-13T12:09:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bicycle-therapeutics-cancer-drug-shows-impressive-65-response-rate-in-phase-1-trial 2025-01-13T12:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/greenwich-lifesciences-expands-flamingo-01-trial-into-france-with-unicancer-partnership 2025-01-13T12:09:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/greenwich-lifesciences-expands-flamingo-01-trial-into-france-with-unicancer-partnership 2025-01-13T12:09:50+00:00 hourly 0.9 https://trial.medpath.com/news/aquestive-therapeutics-outlines-key-2025-objectives-and-business-update 2025-01-13T12:09:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aquestive-therapeutics-outlines-key-2025-objectives-and-business-update 2025-01-13T12:09:31+00:00 hourly 0.9 https://trial.medpath.com/news/normunity-secures-75-million-series-b-financing-to-propel-cancer-therapy-development 2025-01-13T12:09:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/normunity-secures-75-million-series-b-financing-to-propel-cancer-therapy-development 2025-01-13T12:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/adjuvant-libtayo-cemiplimab-shows-significant-improvement-in-disease-free-survival-for-high-risk-cscc-patients 2025-01-13T12:09:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adjuvant-libtayo-cemiplimab-shows-significant-improvement-in-disease-free-survival-for-high-risk-cscc-patients 2025-01-13T12:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/elicera-therapeutics-drug-candidate-elc-100-receives-orphan-drug-designation-in-the-u-s 2025-01-13T12:04:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elicera-therapeutics-drug-candidate-elc-100-receives-orphan-drug-designation-in-the-u-s 2025-01-13T12:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-dosed-in-nci-sponsored-clinical-trial-of-iadademstat-combination-for-aml 2025-01-13T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-dosed-in-nci-sponsored-clinical-trial-of-iadademstat-combination-for-aml 2025-01-13T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/beam-therapeutics-advances-sickle-cell-treatment-and-genetic-disease-therapies 2025-01-13T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beam-therapeutics-advances-sickle-cell-treatment-and-genetic-disease-therapies 2025-01-13T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pulse-biosciences-showcases-nanosecond-pfa-technology-at-af-symposium-2025 2025-01-13T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pulse-biosciences-showcases-nanosecond-pfa-technology-at-af-symposium-2025 2025-01-13T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/schrodinger-advances-in-pharmaceutical-r-d-with-strategic-collaborations-and-clinical-trials 2025-01-13T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/schrodinger-advances-in-pharmaceutical-r-d-with-strategic-collaborations-and-clinical-trials 2025-01-13T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nuvalent-aims-for-first-potential-approval-in-2026-with-new-cancer-treatments 2025-01-13T11:39:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuvalent-aims-for-first-potential-approval-in-2026-with-new-cancer-treatments 2025-01-13T11:39:37+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-to-acquire-intra-cellular-therapies-strengthening-neuroscience-leadership 2025-01-13T11:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-to-acquire-intra-cellular-therapies-strengthening-neuroscience-leadership 2025-01-13T11:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/positive-outlook-for-tyra-bioscience-following-fda-clearance-and-promising-clinical-data 2025-01-13T11:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/positive-outlook-for-tyra-bioscience-following-fda-clearance-and-promising-clinical-data 2025-01-13T11:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/regor-s-obesity-pill-shows-modest-weight-loss-in-phase-2a-advances-to-new-trial 2025-01-13T11:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regor-s-obesity-pill-shows-modest-weight-loss-in-phase-2a-advances-to-new-trial 2025-01-13T11:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/novo-holdings-invests-in-windward-bio-for-immunological-disease-treatments 2025-01-13T11:07:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-holdings-invests-in-windward-bio-for-immunological-disease-treatments 2025-01-13T11:07:05+00:00 hourly 0.9 https://trial.medpath.com/news/stem-cell-and-gene-therapy-breakthroughs-advance-treatment-options-for-parkinson-s-and-amd 2025-01-13T10:58:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stem-cell-and-gene-therapy-breakthroughs-advance-treatment-options-for-parkinson-s-and-amd 2025-01-13T10:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/hmnc-completes-subject-randomisation-in-phase-iib-mdd-treatment-trial 2025-01-13T10:56:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hmnc-completes-subject-randomisation-in-phase-iib-mdd-treatment-trial 2025-01-13T10:56:03+00:00 hourly 0.9 https://trial.medpath.com/news/efficacy-and-safety-of-bi-1358894-in-patients-with-borderline-personality-disorder 2025-01-13T10:35:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/efficacy-and-safety-of-bi-1358894-in-patients-with-borderline-personality-disorder 2025-01-13T10:35:28+00:00 hourly 0.9 https://trial.medpath.com/news/heidelberg-pharma-advances-into-cohort-7-in-phase-i-iia-study-for-multiple-myeloma-treatment 2025-01-13T10:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heidelberg-pharma-advances-into-cohort-7-in-phase-i-iia-study-for-multiple-myeloma-treatment 2025-01-13T10:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/distinct-mechanisms-of-her2-targeting-agents-in-nsclc-understanding-tkis-vs-adcs 2025-01-13T09:56:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/distinct-mechanisms-of-her2-targeting-agents-in-nsclc-understanding-tkis-vs-adcs 2025-01-13T09:56:12+00:00 hourly 0.9 https://trial.medpath.com/news/oric-944-shows-promising-psa-response-in-advanced-prostate-cancer-combination-study 2025-01-13T09:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oric-944-shows-promising-psa-response-in-advanced-prostate-cancer-combination-study 2025-01-13T09:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/cspc-pharmaceutical-gains-approval-for-new-diabetes-drug 2025-01-13T09:38:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cspc-pharmaceutical-gains-approval-for-new-diabetes-drug 2025-01-13T09:38:19+00:00 hourly 0.9 https://trial.medpath.com/news/summit-s-ivonescimab-emerges-as-potential-keytruda-challenger-in-major-cancer-treatment-breakthrough 2025-01-13T09:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/summit-s-ivonescimab-emerges-as-potential-keytruda-challenger-in-major-cancer-treatment-breakthrough 2025-01-13T09:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/integrated-smoking-cessation-program-shows-superior-results-in-lung-cancer-screening-setting 2025-01-13T09:13:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/integrated-smoking-cessation-program-shows-superior-results-in-lung-cancer-screening-setting 2025-01-13T09:13:38+00:00 hourly 0.9 https://trial.medpath.com/news/revolutionizing-drug-development-the-rise-of-targeted-protein-degradation 2025-01-13T09:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revolutionizing-drug-development-the-rise-of-targeted-protein-degradation 2025-01-13T09:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-s-bluerock-advances-parkinson-s-cell-therapy-to-phase-iii 2025-01-13T09:11:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-s-bluerock-advances-parkinson-s-cell-therapy-to-phase-iii 2025-01-13T09:11:42+00:00 hourly 0.9 https://trial.medpath.com/news/advancements-and-challenges-in-clinical-trials-a-2024-overview 2025-01-13T09:07:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancements-and-challenges-in-clinical-trials-a-2024-overview 2025-01-13T09:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/eckert-ziegler-and-glytherix-expand-collaboration-with-actinium-225-supply-agreement 2025-01-13T09:04:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eckert-ziegler-and-glytherix-expand-collaboration-with-actinium-225-supply-agreement 2025-01-13T09:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/scitech-development-advances-st-001-nanofenretinide-to-next-clinical-trial-phase-for-t-cell-lymphoma 2025-01-13T09:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scitech-development-advances-st-001-nanofenretinide-to-next-clinical-trial-phase-for-t-cell-lymphoma 2025-01-13T09:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/spear-bio-s-ptau-217-blood-test-receives-fda-breakthrough-device-designation-for-early-alzheimer-s-diagnosis 2025-01-13T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spear-bio-s-ptau-217-blood-test-receives-fda-breakthrough-device-designation-for-early-alzheimer-s-diagnosis 2025-01-13T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fractyl-health-s-revita-procedure-shows-promise-in-sustained-weight-loss-management 2025-01-13T08:46:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fractyl-health-s-revita-procedure-shows-promise-in-sustained-weight-loss-management 2025-01-13T08:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-significant-ethnic-disparities-in-early-onset-colorectal-cancer-diagnoses-across-nhs 2025-01-13T08:43:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-significant-ethnic-disparities-in-early-onset-colorectal-cancer-diagnoses-across-nhs 2025-01-13T08:43:19+00:00 hourly 0.9 https://trial.medpath.com/news/novel-ctdna-blood-test-shows-promise-in-predicting-lung-cancer-treatment-outcomes 2025-01-13T08:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-ctdna-blood-test-shows-promise-in-predicting-lung-cancer-treatment-outcomes 2025-01-13T08:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/silent-progression-of-glaucoma-expert-highlights-critical-need-for-early-detection 2025-01-13T08:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/silent-progression-of-glaucoma-expert-highlights-critical-need-for-early-detection 2025-01-13T08:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/hvivo-plc-completes-pilot-hmpv-characterisation-study 2025-01-13T08:02:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hvivo-plc-completes-pilot-hmpv-characterisation-study 2025-01-13T08:02:43+00:00 hourly 0.9 https://trial.medpath.com/news/silexion-therapeutics-to-unveil-sil-204-data-for-kras-driven-pancreatic-cancer-at-2025-asco-gi-cancers-symposium 2025-01-13T07:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/silexion-therapeutics-to-unveil-sil-204-data-for-kras-driven-pancreatic-cancer-at-2025-asco-gi-cancers-symposium 2025-01-13T07:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/walden-biosciences-announces-2024-achievements-and-2025-goals 2025-01-13T07:44:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/walden-biosciences-announces-2024-achievements-and-2025-goals 2025-01-13T07:44:49+00:00 hourly 0.9 https://trial.medpath.com/news/telehealth-proves-equally-effective-as-in-person-visits-for-asthma-management-study-shows 2025-01-13T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/telehealth-proves-equally-effective-as-in-person-visits-for-asthma-management-study-shows 2025-01-13T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/elevation-oncology-advances-clinical-trials-for-gastric-gej-cancer-treatment 2025-01-13T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elevation-oncology-advances-clinical-trials-for-gastric-gej-cancer-treatment 2025-01-13T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-to-acquire-idrx-inc-in-a-deal-worth-up-to-1-15-billion 2025-01-13T07:08:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-to-acquire-idrx-inc-in-a-deal-worth-up-to-1-15-billion 2025-01-13T07:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/ai-and-data-science-set-to-transform-life-sciences-industry-by-2025 2025-01-13T07:07:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-and-data-science-set-to-transform-life-sciences-industry-by-2025 2025-01-13T07:07:32+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-therapeutics-sets-strategic-goals-for-2025-with-focus-on-gene-based-medicine-and-clinical-trials 2025-01-13T07:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-therapeutics-sets-strategic-goals-for-2025-with-focus-on-gene-based-medicine-and-clinical-trials 2025-01-13T07:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-new-test-for-b-cell-lymphoma-obtains-fda-clearance 2025-01-13T06:27:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-s-new-test-for-b-cell-lymphoma-obtains-fda-clearance 2025-01-13T06:27:10+00:00 hourly 0.9 https://trial.medpath.com/news/khyber-medical-university-to-conduct-clinical-trials-for-new-leishmaniasis-drug 2025-01-13T06:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/khyber-medical-university-to-conduct-clinical-trials-for-new-leishmaniasis-drug 2025-01-13T06:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/idh1-targeted-therapy-shows-promise-in-improving-mds-patient-outcomes-ash-2024-data-reveals 2025-01-13T06:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/idh1-targeted-therapy-shows-promise-in-improving-mds-patient-outcomes-ash-2024-data-reveals 2025-01-13T06:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/intensity-therapeutics-novel-cancer-drug-int230-6-shows-promise-in-advanced-sarcoma-and-breast-cancer 2025-01-13T06:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intensity-therapeutics-novel-cancer-drug-int230-6-shows-promise-in-advanced-sarcoma-and-breast-cancer 2025-01-13T06:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/scandion-oncology-announces-final-data-from-the-corist-trial 2025-01-13T06:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scandion-oncology-announces-final-data-from-the-corist-trial 2025-01-13T06:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-leads-320m-investment-in-truveta-for-massive-genome-database-project 2025-01-13T06:00:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-leads-320m-investment-in-truveta-for-massive-genome-database-project 2025-01-13T06:00:25+00:00 hourly 0.9 https://trial.medpath.com/news/rion-completes-enrollment-for-phase-2-clinical-study-of-peptm-in-diabetic-foot-ulcers 2025-01-13T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rion-completes-enrollment-for-phase-2-clinical-study-of-peptm-in-diabetic-foot-ulcers 2025-01-13T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4d-150-gene-therapy-shows-promising-results-in-diabetic-macular-edema-trial 2025-01-13T05:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/4d-150-gene-therapy-shows-promising-results-in-diabetic-macular-edema-trial 2025-01-13T05:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/extended-ambulation-period-correlates-with-improved-cardiac-function-in-adult-dmd-patients 2025-01-13T05:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/extended-ambulation-period-correlates-with-improved-cardiac-function-in-adult-dmd-patients 2025-01-13T05:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-hepcidin-mimetic-and-interferons-reshape-polycythemia-vera-treatment-landscape 2025-01-13T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-hepcidin-mimetic-and-interferons-reshape-polycythemia-vera-treatment-landscape 2025-01-13T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nvidia-expands-healthcare-ai-footprint-with-iqvia-illumina-and-mayo-clinic-partnerships 2025-01-13T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nvidia-expands-healthcare-ai-footprint-with-iqvia-illumina-and-mayo-clinic-partnerships 2025-01-13T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/jpm-healthcare-conference-2025-industry-leaders-to-converge-in-san-francisco-for-landmark-biotech-event 2025-01-13T04:40:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jpm-healthcare-conference-2025-industry-leaders-to-converge-in-san-francisco-for-landmark-biotech-event 2025-01-13T04:40:42+00:00 hourly 0.9 https://trial.medpath.com/news/mereo-biopharma-s-setrusumab-shows-promise-in-phase-ii-alvelestat-gains-ema-orphan-status 2025-01-13T04:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mereo-biopharma-s-setrusumab-shows-promise-in-phase-ii-alvelestat-gains-ema-orphan-status 2025-01-13T04:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/olix-pharmaceuticals-confirms-safety-and-tolerability-of-hair-loss-drug-in-australian-phase-1-study 2025-01-13T03:44:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/olix-pharmaceuticals-confirms-safety-and-tolerability-of-hair-loss-drug-in-australian-phase-1-study 2025-01-13T03:44:09+00:00 hourly 0.9 https://trial.medpath.com/news/kmu-to-conduct-clinical-trials-of-new-leishmaniasis-drug 2025-01-13T02:31:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kmu-to-conduct-clinical-trials-of-new-leishmaniasis-drug 2025-01-13T02:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/praxis-precision-medicines-highlights-2025-corporate-strategy-and-business-priorities 2025-01-13T02:11:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/praxis-precision-medicines-highlights-2025-corporate-strategy-and-business-priorities 2025-01-13T02:11:43+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-innovations-in-regenerative-medicine-target-parkinson-s-heart-disease-and-amd 2025-01-13T01:58:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-innovations-in-regenerative-medicine-target-parkinson-s-heart-disease-and-amd 2025-01-13T01:58:09+00:00 hourly 0.9 https://trial.medpath.com/news/tune-therapeutics-secures-175m-for-hepatitis-b-treatment-and-epigenetic-research 2025-01-13T01:08:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tune-therapeutics-secures-175m-for-hepatitis-b-treatment-and-epigenetic-research 2025-01-13T01:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/eversana-transforms-pharmaceutical-commercialization-with-integrated-launch-model 2025-01-13T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eversana-transforms-pharmaceutical-commercialization-with-integrated-launch-model 2025-01-13T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/socazolimab-shows-promise-in-treating-extensive-stage-small-cell-lung-cancer 2025-01-13T00:11:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/socazolimab-shows-promise-in-treating-extensive-stage-small-cell-lung-cancer 2025-01-13T00:11:01+00:00 hourly 0.9 https://trial.medpath.com/news/caribou-biosciences-initiates-cb-010-gallop-phase-1-trial-in-lupus 2025-01-13T00:09:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caribou-biosciences-initiates-cb-010-gallop-phase-1-trial-in-lupus 2025-01-13T00:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-drug-durvalumab-shows-promise-in-increasing-survival-rates-for-bladder-cancer-patients 2025-01-13T00:03:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunotherapy-drug-durvalumab-shows-promise-in-increasing-survival-rates-for-bladder-cancer-patients 2025-01-13T00:03:23+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-achieves-ce-mark-approval-for-brainsensetm-adaptive-deep-brain-stimulation 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-achieves-ce-mark-approval-for-brainsensetm-adaptive-deep-brain-stimulation 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/editas-medicine-advances-in-gene-editing-with-new-preclinical-data-and-strategic-priorities 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/editas-medicine-advances-in-gene-editing-with-new-preclinical-data-and-strategic-priorities 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/scholar-rock-s-stock-soars-440-following-positive-sapphire-trial-results 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scholar-rock-s-stock-soars-440-following-positive-sapphire-trial-results 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lutetium-177-psma-radioligand-therapy-shows-promising-results-in-early-line-treatment-of-metastatic-castration-resistant-prostate-cancer 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lutetium-177-psma-radioligand-therapy-shows-promising-results-in-early-line-treatment-of-metastatic-castration-resistant-prostate-cancer 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-explores-first-line-use-of-kras-inhibitor-lumakras-in-nsclc-treatment 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-explores-first-line-use-of-kras-inhibitor-lumakras-in-nsclc-treatment 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bridge-biotherapeutics-partners-with-brainomix-to-leverage-ai-in-lung-fibrosis-trial 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bridge-biotherapeutics-partners-with-brainomix-to-leverage-ai-in-lung-fibrosis-trial 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-skyrizi-r-risankizumab-now-available-on-nhs-scotland-for-ulcerative-colitis-treatment 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-s-skyrizi-r-risankizumab-now-available-on-nhs-scotland-for-ulcerative-colitis-treatment 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nurix-therapeutics-sets-ambitious-2025-goals-for-cancer-and-autoimmune-disease-treatments 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nurix-therapeutics-sets-ambitious-2025-goals-for-cancer-and-autoimmune-disease-treatments 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-finds-hipec-does-not-improve-outcomes-for-recurrent-epithelial-ovarian-cancer 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-finds-hipec-does-not-improve-outcomes-for-recurrent-epithelial-ovarian-cancer 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-study-confirms-metformin-s-safety-profile-matches-insulin-for-diabetes-management-during-pregnancy 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-study-confirms-metformin-s-safety-profile-matches-insulin-for-diabetes-management-during-pregnancy 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novavax-launches-phase-3-trial-for-covid-19-influenza-combination-vaccine 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novavax-launches-phase-3-trial-for-covid-19-influenza-combination-vaccine 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/libtayo-cemiplimab-shows-promising-results-in-advanced-skin-cancer-treatment 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/libtayo-cemiplimab-shows-promising-results-in-advanced-skin-cancer-treatment 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cmu-and-healthcare-system-secures-unprecedented-17-awards-at-the-2024-taiwan-national-innovation-awards 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cmu-and-healthcare-system-secures-unprecedented-17-awards-at-the-2024-taiwan-national-innovation-awards 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cms-initiates-national-coverage-analysis-for-medtronic-s-renal-denervation-system 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cms-initiates-national-coverage-analysis-for-medtronic-s-renal-denervation-system 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cellectar-biosciences-advances-in-cancer-treatment-research 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellectar-biosciences-advances-in-cancer-treatment-research 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-seeks-earlier-line-use-of-breyanzi-in-lymphoma-following-trial-success 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-seeks-earlier-line-use-of-breyanzi-in-lymphoma-following-trial-success 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ascendis-pharma-a-s-announces-key-updates-and-achievements-in-2024 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascendis-pharma-a-s-announces-key-updates-and-achievements-in-2024 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/combination-therapy-of-ibrutinib-and-rituximab-shows-promise-in-treating-cgvhd 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/combination-therapy-of-ibrutinib-and-rituximab-shows-promise-in-treating-cgvhd 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-on-diacylglycerol-edible-oil-s-impact-on-chronic-metabolic-syndrome-patients-with-hyperuricemia 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-on-diacylglycerol-edible-oil-s-impact-on-chronic-metabolic-syndrome-patients-with-hyperuricemia 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novavax-achieves-first-50-million-milestone-in-sanofi-partnership-advancing-covid-19-and-influenza-vaccine-development 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novavax-achieves-first-50-million-milestone-in-sanofi-partnership-advancing-covid-19-and-influenza-vaccine-development 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/smartphone-app-enhances-knowledge-and-symptom-management-for-rcc-patients-on-ici-tki-therapy 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smartphone-app-enhances-knowledge-and-symptom-management-for-rcc-patients-on-ici-tki-therapy 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-of-neurosigma-s-monarch-etns-system-for-adhd-completes-enrollment 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-of-neurosigma-s-monarch-etns-system-for-adhd-completes-enrollment 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/r3-vascular-secures-wcg-irb-approval-and-cms-category-b-medicare-coverage-for-elite-btk-pivotal-trial 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/r3-vascular-secures-wcg-irb-approval-and-cms-category-b-medicare-coverage-for-elite-btk-pivotal-trial 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-halts-development-of-eliapixant-due-to-safety-concerns 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-halts-development-of-eliapixant-due-to-safety-concerns 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-blood-test-shows-71-accuracy-in-detecting-pancreatic-cancer-advancing-toward-clinical-use 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-blood-test-shows-71-accuracy-in-detecting-pancreatic-cancer-advancing-toward-clinical-use 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/transcode-therapeutics-advances-in-phase-1-clinical-trial-for-ttx-mc138-a-novel-rna-oncology-treatment 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transcode-therapeutics-advances-in-phase-1-clinical-trial-for-ttx-mc138-a-novel-rna-oncology-treatment 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/actinogen-s-lead-drug-xanamem-gains-who-recognition-amid-ongoing-trials 2025-01-12T23:33:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actinogen-s-lead-drug-xanamem-gains-who-recognition-amid-ongoing-trials 2025-01-12T23:33:06+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-pharmaceuticals-inc-vrtx-announces-significant-program-updates-ahead-of-2025 2025-01-12T23:15:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertex-pharmaceuticals-inc-vrtx-announces-significant-program-updates-ahead-of-2025 2025-01-12T23:15:05+00:00 hourly 0.9 https://trial.medpath.com/news/xilio-therapeutics-strengthens-leadership-team-with-new-chief-legal-officer-amid-advancement-of-tumor-activated-immunotherapy-pipeline 2025-01-12T23:08:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xilio-therapeutics-strengthens-leadership-team-with-new-chief-legal-officer-amid-advancement-of-tumor-activated-immunotherapy-pipeline 2025-01-12T23:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/cellectar-biosciences-to-showcase-2025-strategic-initiatives-and-clinical-advancements-at-biotech-showcase 2025-01-12T23:06:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellectar-biosciences-to-showcase-2025-strategic-initiatives-and-clinical-advancements-at-biotech-showcase 2025-01-12T23:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/cingulate-stock-rated-buy-by-roth-mkm-anticipates-1-6b-sales-potential 2025-01-12T22:19:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cingulate-stock-rated-buy-by-roth-mkm-anticipates-1-6b-sales-potential 2025-01-12T22:19:21+00:00 hourly 0.9 https://trial.medpath.com/news/reviva-pharmaceuticals-stock-rated-buy-by-roth-mkm-backed-by-phase-3-results 2025-01-12T22:19:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reviva-pharmaceuticals-stock-rated-buy-by-roth-mkm-backed-by-phase-3-results 2025-01-12T22:19:20+00:00 hourly 0.9 https://trial.medpath.com/news/blueprint-medicines-provides-2025-outlook-and-highlights-strategy-for-continued-growth 2025-01-12T21:42:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blueprint-medicines-provides-2025-outlook-and-highlights-strategy-for-continued-growth 2025-01-12T21:42:39+00:00 hourly 0.9 https://trial.medpath.com/news/ideaya-biosciences-receives-buy-rating-due-to-strong-pipeline-and-financial-health 2025-01-12T21:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ideaya-biosciences-receives-buy-rating-due-to-strong-pipeline-and-financial-health 2025-01-12T21:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/alnylam-reports-strong-33-growth-sets-ambitious-2-25b-revenue-target-for-2025 2025-01-12T21:20:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alnylam-reports-strong-33-growth-sets-ambitious-2-25b-revenue-target-for-2025 2025-01-12T21:20:35+00:00 hourly 0.9 https://trial.medpath.com/news/regulatory-complexity-and-supply-chain-challenges-shape-apac-clinical-services-landscape 2025-01-12T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regulatory-complexity-and-supply-chain-challenges-shape-apac-clinical-services-landscape 2025-01-12T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/alnylam-announces-preliminary-fourth-quarter-and-full-year-2024-financial-results-and-2025-outlook 2025-01-12T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alnylam-announces-preliminary-fourth-quarter-and-full-year-2024-financial-results-and-2025-outlook 2025-01-12T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/geode-capital-management-llc-increases-stake-in-maia-biotechnology-inc 2025-01-12T20:28:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geode-capital-management-llc-increases-stake-in-maia-biotechnology-inc 2025-01-12T20:28:48+00:00 hourly 0.9 https://trial.medpath.com/news/ideaya-biosciences-announces-strategic-updates-at-jp-morgan-healthcare-conference 2025-01-12T18:38:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ideaya-biosciences-announces-strategic-updates-at-jp-morgan-healthcare-conference 2025-01-12T18:38:29+00:00 hourly 0.9 https://trial.medpath.com/news/molecular-partners-announces-clinical-expansion-and-radiopharma-strategy-at-j-p-morgan-healthcare-conference 2025-01-12T18:25:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/molecular-partners-announces-clinical-expansion-and-radiopharma-strategy-at-j-p-morgan-healthcare-conference 2025-01-12T18:25:11+00:00 hourly 0.9 https://trial.medpath.com/news/ultragenyx-announces-preliminary-2024-revenue-and-2025-financial-guidance-along-with-pipeline-updates 2025-01-12T16:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ultragenyx-announces-preliminary-2024-revenue-and-2025-financial-guidance-along-with-pipeline-updates 2025-01-12T16:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/leyden-labs-secures-70-million-to-advance-intranasal-antibody-programs 2025-01-12T15:42:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leyden-labs-secures-70-million-to-advance-intranasal-antibody-programs 2025-01-12T15:42:42+00:00 hourly 0.9 https://trial.medpath.com/news/bacteriophages-a-potential-ally-against-superbugs 2025-01-12T15:35:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bacteriophages-a-potential-ally-against-superbugs 2025-01-12T15:35:56+00:00 hourly 0.9 https://trial.medpath.com/news/curevo-announces-positive-updated-phase-2-data-for-amezosvatein-shingles-vaccine 2025-01-12T15:17:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curevo-announces-positive-updated-phase-2-data-for-amezosvatein-shingles-vaccine 2025-01-12T15:17:54+00:00 hourly 0.9